Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults
Official Title
A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults
Acronym
Not provided
Organization
National Institute of Allergy and Infectious Diseases (NIAID)NIH
Status Module
Record Verification Date
Apr 20, 2022
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Mar 25, 2021Actual
Primary Completion Date
Sep 15, 2023Actual
Completion Date
Sep 15, 2023Actual
First Submitted Date
Feb 25, 2021
First Submission Date that Met QC Criteria
Feb 25, 2021
First Posted Date
Mar 1, 2021Actual
Results Waived
Not provided
Results First Submitted Date
Sep 5, 2024
Results First Submitted that Met QC Criteria
Jan 9, 2025
Results First Posted Date
Jan 31, 2025Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
May 8, 2025
Last Update Posted Date
May 16, 2025Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)NIH
Collaborators
Name
Class
Gritstone bio, Inc.
INDUSTRY
Oversight Module
Has Data Monitoring Committee (DMC)
Not provided
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
No
FDAAA801 Violation
Not provided
Description Module
Brief Summary
This is a multicenter, US-only, phase 1, open-label, dose escalation, non-randomized study of the safety, tolerability, and immunogenicity of investigational ChAd and SAM SARS-CoV-2 vaccines in healthy adult subjects. Homologous and heterologous prime-boost vaccination schedules (Stage 1), as well as boost(s) after receipt of COVID-19 EUA/licensed vaccines (Stage 2) will be examined. Subjects' willingness to receive ChAd vaccines will be assessed and documented at the time of informed consent and considered to determine group assignments. This phase 1 study will enroll 17 Stage 1 and up to 118 Stage 2 subjects. Eligible subjects will be enrolled in different groups based on their age (18-60 years old and >60 years old) and their EUA/licensed COVID-19 vaccination status. A sentinel approach with 72-hour (Stage 1, and Stage 2, Groups 5, 6, 8-10, 12, 13-15) or 7-day observation times (Groups 7 and 11) will be used, before recruiting the remainder of each dose escalation group. Decisions about dose escalation will be determined by the SSC with consultation with the DSMB as needed after all subjects in each group have been observed through Day 8 post first study vaccination. All subjects will be followed through 12 months after their last study vaccination. Vaccinated subjects will be carefully monitored for exposure and infection to SARS-CoV-2 throughout the study. Escalation to the highest dose (10 µg) of SAM-S-TCE in younger subjects will proceed only following safety assessments of the 10 µg dose in older subjects for a period of 28 days post-vaccination. In addition, the dosage of SAM-S-TCE given as a double boost to subjects previously vaccinated with the Johnson & Johnson/Janssen Ad26 COVID-19 EUA/licensed vaccine in Groups 8A, 8B, and 12A, 12B will be determined based on the dose escalation reactogenicity and immunogenicity results in Groups 5-7 and 9-11, respectively. After protocol version 9.0 was implemented, it was decided not to enroll subjects into Groups 7 and 8 because of competing priorities and predicted difficulties enrolling into these two groups.
The primary objectives of this study are 1) To assess the safety and tolerability of different doses of ChAd-S or ChAd-S-TCE, and SAM-S or SAM-S-TCE when administered as prime-boost in healthy naïve adult subjects, 2) To assess the safety and tolerability of different doses of ChAd-S or ChAd-S-TCE, and SAM-S or SAM-S-TCE when administered as first or second boost in healthy adult subjects previously vaccinated with an mRNA or adenoviral-vectored COVID-19 EUA/licensed vaccine.
Detailed Description
This is a multicenter, US-only, phase 1, open-label, dose escalation, non-randomized study of the safety, tolerability, and immunogenicity of investigational ChAd and SAM SARS-CoV-2 vaccines in healthy adult subjects. Homologous and heterologous prime-boost vaccination schedules (Stage 1), as well as boost(s) after receipt of COVID-19 EUA/licensed vaccines (Stage 2) will be examined. Subjects' willingness to receive ChAd vaccines will be assessed and documented at the time of informed consent and considered to determine group assignments. This phase 1 study will enroll 17 Stage 1 and up to 118 Stage 2 subjects. Eligible subjects will be enrolled in different groups based on their age (18-60 years old and >60 years old) and their EUA/licensed COVID-19 vaccination status. A sentinel approach with 72-hour (Stage 1, and Stage 2, Groups 5, 6, 8-10, 12, 13-15) or 7-day observation times (Groups 7 and 11) will be used, before recruiting the remainder of each dose escalation group. Decisions about dose escalation will be determined by the SSC with consultation with the DSMB as needed after all subjects in each group have been observed through Day 8 post first study vaccination. All subjects will be followed through 12 months after their last study vaccination. Vaccinated subjects will be carefully monitored for exposure and infection to SARS-CoV-2 throughout the study. Escalation to the highest dose (10 µg) of SAM-S-TCE in younger subjects will proceed only following safety assessments of the 10 µg dose in older subjects for a period of 28 days post-vaccination. In addition, the dosage of SAM-S-TCE given as a double boost to subjects previously vaccinated with the Johnson & Johnson/Janssen Ad26 COVID-19 EUA/licensed vaccine in Groups 8A, 8B, and 12A, 12B will be determined based on the dose escalation reactogenicity and immunogenicity results in Groups 5-7 and 9-11, respectively. After protocol version 9.0 was implemented, it was decided not to enroll subjects into Groups 7 and 8 because of competing priorities and predicted difficulties enrolling into these two groups.
The primary objectives of this study are 1) To assess the safety and tolerability of different doses of ChAd-S or ChAd-S-TCE, and SAM-S or SAM-S-TCE when administered as prime-boost in healthy naïve adult subjects, 2) To assess the safety and tolerability of different doses of ChAd-S or ChAd-S-TCE, and SAM-S or SAM-S-TCE when administered as first or second boost in healthy adult subjects previously vaccinated with an mRNA or adenoviral-vectored COVID-19 EUA/licensed vaccine. The secondary objective of this study is to assess the humoral immunogenicity of ChAd-S or ChAd-S-TCE, and SAM-S or SAM-S-TCE.
Conditions Module
Conditions
COVID-19
Keywords
Immunogenicity
Prime-Boost
Reactogenicity
Safety
SARS-CoV-2
vaccine
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 1
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
81Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Stage 1 (Naïve) Group 1
Experimental
5 x 10^10 viral particles of ChAdV68-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=4
Biological: ChAdV68-S
Biological: SAM-LNP-S
Other: Sodium Chloride, 0.9%
Stage 1 (Naïve) Group 3A
Experimental
30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=3
Biological: SAM-LNP-S
Other: Sodium Chloride, 0.9%
Stage 1 (Naïve) Group 3B
Experimental
30 mcg SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-LNP-S administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=7
Biological: SAM-LNP-S
Other: Sodium Chloride, 0.9%
Stage 1 (Naïve) Group 4
Experimental
10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=3
Interventions
Name
Type
Description
Arm Group Labels
Other Names
ChAdV68-S
Biological
Chimpanzee Adenovirus serotype 68 - Spike (ChAdV68-S) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5 mL intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)
Number of participants that experienced any NOCMCs during the course of the study
Day 1 to study completion through up to 1 year post last dose
Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)
Number of participants that experienced any PIMMCs during the course of the study
Day 1 to study completion through up to 1 year post last dose
Frequency of Any Medically Attended Adverse Events (MAAEs)
Number of participants that experienced any MAAEs during the course of the study
Day 1 to study completion through up to 1 year post last dose
Frequency of Any Laboratory AE
Number of participants that experienced any laboratory AE
Through 7 days post each study vaccination
Frequency of Any Serious Adverse Events (SAEs)
The number of participants that experience any SAEs from Day 1 to study completion. An AE or suspected adverse reaction is considered serious if, in the view of either the participating site PI or appropriate sub-investigator or the sponsor, it results in: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
Day 1 to study completion through up to 1 year post last dose
Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)
Number of participants who experienced any systemic solicited AEs through 7 days post any vaccination. Systemic events include: fatigue, headache, myalgia, arthralgia, nausea, chills and fever.
Secondary Outcomes
Measure
Description
Time Frame
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Day 29 Post Vaccination 1, Day 57 Post Vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Subjects eligible to participate in this trial must meet all of the following inclusion criteria:
Provide written informed consent prior to initiation of any study procedures
Able and willing (in the investigator's opinion) to comply with all study requirements
Are men or non-pregnant women aged 18 years or older at enrollment
Are in good health*
*As defined by absence of clinically significant medical conditions defined by the CDC as increasing risk for severe corona virus disease-19 (COVID-19) (see exclusion criteria), or other acute or chronic medical conditions determined by medical history, physical examination (PE), screening laboratory test results, and/or clinical assessment of the investigator that are either listed as exclusion criteria below or in the opinion of the investigator would increase risk for study participation or affect the assessment of the safety of subjects. Chronic medical conditions should be stable for the last 60 days (no hospitalizations, emergency room or urgent care for condition, or invasive medical procedures). Any prescription change that is due to change of health care provider, insurance company, etc., or done for financial reasons, and in the same class of medication, will not be considered a deviation of this inclusion criterion. Any change in prescription medication due to improvement of a disease outcome, as determined by the participating site PI or appropriate sub- investigator, will not be considered a deviation of this inclusion criterion. Subjects may be on chronic or as needed (prn) medications if, in the opinion of the participating site PI or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity, and do not indicate a worsening of medical diagnosis/condition. Similarly, medication changes in the 60 days prior to enrollment as well as subsequent to enrollment and study vaccination are acceptable provided the change was not precipitated by deterioration in the chronic medical condition, and there is no anticipated additional risk to the subject or interference with the evaluation of responses to study vaccination.
Agree to refrain from blood donation during the course of the study
Plan to remain living in the area for the duration of the study
Women of childbearing potential (WOCBP)* must plan to avoid pregnancy for at least 60 days after the last study vaccination and be willing to use an adequate method of contraception** consistently for 30 days prior to first study vaccine and for at least 60 days after the last study vaccine.
*Not sterilized via bilateral oophorectomy, tubal ligation/salpingectomy, hysterectomy, or successful Essure (R) placement (permanent, non-surgical, non-hormonal sterilization with documented radiological confirmation test at least 90 days after the procedure); still menstruating; or < 1 year has passed since the last menses if menopausal
**Acceptable methods of birth control include the following: oral contraceptives, injection hormonal contraceptive, implant hormonal contraceptive, hormonal patch, intrauterine device, spermicidal products and barrier methods (such as cervical sponge, diaphragm, or condom with spermicide), abstinence, monogamous with a vasectomized partner, non-male sexual relationship
Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to each study vaccination
Oral temperature < 37.8 degrees Celsius (100.0 degrees Fahrenheit)
Clinical screening lab evaluations (white blood cell (WBC), hemoglobin (HgB), platelets (PLT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (T Bili), creatine kinase (CK), serum creatinine (Cr) and prothrombin time (PT)/partial thromboplastin time (PTT)) are within acceptable normal reference ranges at the clinical lab being used* *With the exception that ALT, AST, ALP, and creatinine values that are below the reference range will not be exclusionary as these values below reference range are clinically insignificant. Any other screening lab value outside the reference range that is thought to be clinically insignificant by a site investigator must be discussed with the DMID Medical Officer prior to enrollment.
Must agree to genetic testing and storage of samples for secondary research
Received at least 2 doses of EUA/licensed mRNA vaccines or at least 1 dose of Ad26 vaccine followed by an mRNA booster, with the last COVID-19 vaccine dose given at least 112 days prior to enrollment (Stage 2 only), as confirmed via CDC vaccination card or other appropriate documentation. Subjects may or may not have been previously infected with SARS-CoV-2.
A subject must meet all of the following criteria to be eligible for leukapheresis:
Written informed consent for leukapheresis is provided
Weight > / = 110 pounds
Screening laboratory evaluations are within acceptable ranges at the site where the leukapheresis procedure will be performed
Negative urine or serum pregnancy test at screening and on the day of the leukapheresis procedure for women of childbearing potential
Adequate bilateral antecubital venous access
No use of blood thinners, aspirin, or nonsteroidal anti-inflammatory drugs (NSAIDs) at least 5 days before the leukapheresis procedure
Exclusion Criteria:
Subjects eligible to participate in this trial must not meet any of the following exclusion criteria:
History of prior confirmed (PCR or antigen test positive) COVID-19 less than 112 days prior to enrollment.
Positive for anti-nucleoprotein SARS-CoV-2 specific antibody by enzyme-linked immunosorbent assay (ELISA) and had the history of upper respiratory illness (URI) compatible with COVID-19 during the 112 days prior to enrollment (seropositivity without a history of URI during the 112 days prior to enrollment will be considered remotely infected persons eligible for enrollment).
Positive nasal swab polymerase chain reaction (PCR) at screening.
Body mass index (BMI) > 30 kg/m^2 for Stage 1 participants and BMI > 35 kg/m^2 for Stage 2 participants.
Presence of medical comorbidities that would place the subject at increased risk for severe COVID-19*
Increased risk of occupational exposure to SARS-CoV-2 (healthcare workers and emergency response personnel)*
*Applies to Stage 1 participants only
Prior receipt of an approved/licensed or investigational SARS-CoV-2 vaccine (including under EUA)*, approved or investigational adenovirus-vectored vaccines**, or any other approved or investigational vaccine likely to impact the interpretation of the trial data.
*Exclusion of prior receipt of EUA/licensed COVID-19 vaccines applies to Stage 1 participants only.
**With the exception of prior receipt of EUA/licensed Johnson & Johnson/Janssen Ad 26 COVID-19 vaccine which is permitted for Groups 8A, 8B, 12A, and 12B.
On current treatment or prevention agents with activity against SARS-CoV-2
Current smoking or vaping or history of smoking or vaping in prior year*
*Applies to Stage 1 participants only
Breastfeeding, pregnant, or planning to become pregnant during the course of the study.
Participation in another research study involving receipt of an investigational product in the 60 days preceding enrolment or planned use during the study period
Receipt or planned receipt of any live, attenuated vaccine within 28 days before or after study vaccination
Receipt or planned receipt of any subunit or killed vaccine within 14 days before or after vaccination
Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of first study vaccination or at any time during the study
Any confirmed or suspected immunosuppressive or immunodeficient state, including human immunodeficiency virus (HIV) infection, asplenia, recurrent, severe infections and chronic (more than 14 continuous days) immunosuppressant medication within the past 6 months (inhaled, ophthalmic, and topical steroids are allowed)
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, including urticaria, respiratory difficulty or abdominal pain (or any immediate allergic reaction of any severity to polysorbate due to potential cross-reactive hypersensitivity with the polyethylene glycol component of the vaccine)
Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema
Any history of anaphylaxis, including but not limited to reaction to vaccination
Any history of severe allergic drug reaction
History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
History of serious ongoing, unstable psychiatric condition that in the opinion of the investigator would interfere with study participation
Seizure in the past 3 years or treatment for seizure disorder in the past 3 years
Bleeding disorder (e.g., factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture or family history of bleeding disorder
Recent (within the past 3 months) surgery, immobility, chronic infection, or head trauma that could increase the risks of thrombosis.
Suspected or known current alcohol abuse. Suspected or known drug abuse in the 5 years preceding enrollment
Seropositive for HIV, hepatitis B surface antigen (HBsAg), or seropositive for hepatitis C virus (antibodies to HCV)
Have an acute illness* within 72 hours prior to study vaccination
*An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the site PI or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol
History of venous or arterial thrombosis or any known thrombophilic condition including heparin-induced thrombocytopenia (HIT) or family history of thrombosis.
History of myocarditis or pericarditis.
History of Guillain-Barre Syndrome (GBS).
Receiving heparin treatment or on medications associated with increased risk of bleeding or thrombosis.
Any other condition that in the opinion of the investigator would pose a health risk to the participant if enrolled or could interfere with evaluation of the trial vaccine or interpretation of study results
Accepts Healthy Volunteers
Yes
Sex
All
Sex/Gender Based
Not provided
Sex/Gender Description
Not provided
Minimum Age
18 Years
Maximum Age
99 Years
Standard Ages
AdultOlder Adult
Study Population
Not provided
Sampling Method
Not provided
Contacts/Locations Module
Central Contacts
Not provided
Overall Officials
Not provided
Locations
Facility
Status
City
State
ZIP
Country
Contacts
The Hope Clinic of Emory University
Decatur
Georgia
30030-1705
United States
Saint Louis University Center for Vaccine Development
Whitaker JA, Rebolledo PA, Abate G, Babu TM, Rouphael NG, Wald A, El Sahly HM, Jooss K, Hart MG, Makowski M, Mu J, Carmack A, Archer JI, Roberts PC, Makhene M, Posavad CM, McElrath MJ, De Rosa SC, Coler R, Montefiori D, Eaton A, Suthar MS, Atmar RL, Hoft DF; DMID 20-0034 Study Team. The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults. Vaccine. 2026 Apr 2;77:128358. doi: 10.1016/j.vaccine.2026.128358. Epub 2026 Feb 25.
See Also Links
Not provided
Available IPD Information
Not provided
IPD Sharing Statement Module
No data available
No data is available for this block.
Results Section
Participant Flow Module
Pre-assignment Details
Stage 1 studied dose escalation of homologous and heterologous prime-boost vaccination schedules in healthy naïve adult participants. Stage 2 studied booster vaccination(s) in adult participant who previously received Coronavirus Disease 2019 (COVID-19) Emergency Use Authorization (EUA)/licensed vaccines.
Recruitment Details
Participants were recruited from 4 distinct US-based Infectious Diseases Clinical Research Consortium (IDCRC) sites. The first participant was enrolled on March 25, 2021, and the last participant was enrolled on September 29, 2022.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Stage 1 (Naïve) Group 1
5 x 10^10 viral particles of ChAdV68-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=4
ChAdV68-S: Chimpanzee Adenovirus serotype 68 - Spike (ChAdV68-S) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5 mL intramuscular injection will be administered in the deltoid muscle.
SAM-LNP-S: Self-Amplifying mRNA - Lipid Nanoparticles - Spike (SAM-LNP-S) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 mL or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Sodium Chloride, 0.9%: The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
Periods
Title
Milestones
Reasons Not Completed
Overall Study
Type
Comment
Milestone Data
STARTED
Baseline Characteristics Module
Baseline Analysis Population Description
Outcome Measures Module
Outcome Measures
Adverse Events Module
Frequency Threshold
5
More Info Module
Limitations and Caveats
Not provided
Annotation Section
No data available
No data is available for this block.
Document Section
Large Document Module
Document Has No Statistical Analysis Plan (SAP)
Not provided
Uploaded Document Information
Type
Includes Protocol
Includes SAP
Includes ICF
Document Label
Document Date
Document Uploaded Date
Document File Name
Prot
Yes
No
No
Study Protocol
Oct 4, 2022
May 31, 2024
Derived Section
Miscellaneous Info Module
Version Holder
Jul 10, 2026
Removed Countries
Not provided
Submission Tracking
No data available
No data is available for this block.
Condition Browse Module
MeSH Terms
Intervention Browse Module
MeSH Terms
Non-Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Not provided
Primary Purpose
Prevention
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
None (Open Label)
Masking Description
Not provided
Who Masked
Not provided
Biological: SAM-LNP-S-TCE
Other: Sodium Chloride, 0.9%
Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 13
Experimental
5 x 10^10 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and on or after Day 113 in participants older than 60 years of age. N=7-10
Biological: ChAdV68-S-TCE
Other: Sodium Chloride, 0.9%
Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 14
Experimental
1 x 10^11 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
Biological: ChAdV68-S-TCE
Other: Sodium Chloride, 0.9%
Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 15
Experimental
5 x 10^11 viral particles of ChAdV68-S-TCE administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
Biological: ChAdV68-S-TCE
Other: Sodium Chloride, 0.9%
Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 10A,B
Experimental
6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8-12
Biological: SAM-LNP-S-TCE
Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 11A,B
Experimental
10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8-12
Biological: SAM-LNP-S-TCE
Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 12A,B
Experimental
10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants older than 60 years of age. N=8-12
Biological: SAM-LNP-S-TCE
Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 9
Experimental
3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8
Biological: SAM-LNP-S-TCE
Other: Sodium Chloride, 0.9%
Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 5
Experimental
3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
Biological: SAM-LNP-S-TCE
Other: Sodium Chloride, 0.9%
Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 6
Experimental
6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
Biological: SAM-LNP-S-TCE
Other: Sodium Chloride, 0.9%
Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 7A,B
Experimental
10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=8-12
Biological: SAM-LNP-S-TCE
Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 8A,B
Experimental
10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants from 18 to 60 years of age. N=8-12
Biological: SAM-LNP-S-TCE
Stage 1 (Naïve) Group 1
ChAdV68-S-TCE
Biological
Chimpanzee Adenovirus 68 - Spike plus additional SARS-CoV-2 T cell epitopes (ChAdV68-S-TCE) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5- or 1.0-mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 13
Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 14
Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 15
SAM-LNP-S
Biological
Self-Amplifying mRNA - Lipid Nanoparticles - Spike (SAM-LNP-S) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 mL or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Stage 1 (Naïve) Group 1
Stage 1 (Naïve) Group 3A
Stage 1 (Naïve) Group 3B
SAM-LNP-S-TCE
Biological
Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Stage 1 (Naïve) Group 4
Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 5
Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 6
Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 7A,B
Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 8A,B
Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 10A,B
Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 11A,B
Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 12A,B
Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 9
Sodium Chloride, 0.9%
Other
The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
Stage 1 (Naïve) Group 1
Stage 1 (Naïve) Group 3A
Stage 1 (Naïve) Group 3B
Stage 1 (Naïve) Group 4
Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 13
Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 14
Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 15
Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 5
Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 6
Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 9
Day 1 through Day 8 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and through 7 days post any vaccination for Groups 1, 3A, 3b and 4.
Frequency of Local Solicited Reactogenicity Adverse Events (AEs)
Number of participants who experienced any local solicited AEs through 7 days post any vaccination. Local events include: pain at injection site, erythema, and induration.
Day 1 through Day 8 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and through 7 days post any vaccination for Groups 1, 3A, 3b and 4.
Frequency of Any Unsolicited Adverse Events (AEs)
Number of participants who experienced any unsolicited AEs through 28 days post vaccination
Day 1 through Day 29 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and 28 days post any vaccination for Groups 1, 3A, 3b and 4.
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Day 57 Post Vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Day 169 Post Vac 1 (85 Days Post Vac 2), Day 265 Post Vac 1 (181 Days Post Vac 2), Day 450 Post Vac 1 (366 Days Post Vac 2)
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1
Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2), Day 265 Post Vaccination 1 (181 Days Post Vaccination 2), Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G
Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1
Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5
Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A
Geometric Mean of RBD titer
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4
Geometric Mean of RBD titer
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean of RBD titer
Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A
Geometric Mean of S-2P titer
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4
Geometric Mean of S-2P titer
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean of S-2P titer
Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G S-2P
Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 1 and 3A
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1 S-2P
Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 1 and 3A
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5 S-2P
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G S-2P
Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.1 S-2P
Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 3B and 4
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.4/5 S-2P
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2), Day 265 Post Vaccination 1 (181 Days Post Vaccination 2), Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against D614G S-2P
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.1 S-2P
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.4/5 S-2P
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Day 1 Pre-Vaccination, Day 15 Post Vaccination
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A
Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A
Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A
Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A
Mean spot forming units per million of the S1 as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A
Mean spot forming units per million of the S2 as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A
Mean spot forming units per million of the Spike as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A
Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4
Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4
Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4
Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4
Mean spot forming units per million of the S1 as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4
Mean spot forming units per million of the S2 as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4
Mean spot forming units per million of the Spike as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4
Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot.
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot.
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot.
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot.
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot.
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot.
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot.
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the S1 as measured by ELISpot.
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the S2 as measured by ELISpot.
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the Spike as measured by ELISpot.
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot.
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1
Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1
Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1
Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
Day 29 Post Vaccination 1
St Louis
Missouri
63104-1015
United States
Baylor College of Medicine
Houston
Texas
77030-3411
United States
The University of Washington - Virology Research Clinic
Seattle
Washington
98104
United States
FG001
Stage 1 (Naïve) Group 3A
30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=3
SAM-LNP-S: Self-Amplifying mRNA - Lipid Nanoparticles - Spike (SAM-LNP-S) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 mL or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Sodium Chloride, 0.9%: The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
FG002
Stage 1 (Naïve) Group 3B
30 mcg SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-LNP-S administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=7
SAM-LNP-S: Self-Amplifying mRNA - Lipid Nanoparticles - Spike (SAM-LNP-S) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 mL or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Sodium Chloride, 0.9%: The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
FG003
Stage 1 (Naïve) Group 4
10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=3
SAM-LNP-S-TCE: Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Sodium Chloride, 0.9%: The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
FG004
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
SAM-LNP-S-TCE: Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Sodium Chloride, 0.9%: The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
FG005
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
SAM-LNP-S-TCE: Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Sodium Chloride, 0.9%: The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
FG006
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 7A,B
10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=8-12
SAM-LNP-S-TCE: Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
FG007
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 8A,B
10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants from 18 to 60 years of age. N=8-12
SAM-LNP-S-TCE: Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
FG008
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8
SAM-LNP-S-TCE: Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Sodium Chloride, 0.9%: The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
FG009
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8-12
SAM-LNP-S-TCE: Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
FG010
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8-12
SAM-LNP-S-TCE: Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
FG011
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 12A,B
10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants older than 60 years of age. N=8-12
SAM-LNP-S-TCE: Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
FG012
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
5 x 10^10 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
ChAdV68-S-TCE: Chimpanzee Adenovirus 68 - Spike plus additional SARS-CoV-2 T cell epitopes (ChAdV68-S-TCE) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5- or 1.0-mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Sodium Chloride, 0.9%: The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
FG013
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
1 x 10^11 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
ChAdV68-S-TCE: Chimpanzee Adenovirus 68 - Spike plus additional SARS-CoV-2 T cell epitopes (ChAdV68-S-TCE) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5- or 1.0-mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Sodium Chloride, 0.9%: The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
FG014
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
5 x 10^11 viral particles of ChAdV68-S-TCE administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
ChAdV68-S-TCE: Chimpanzee Adenovirus 68 - Spike plus additional SARS-CoV-2 T cell epitopes (ChAdV68-S-TCE) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5- or 1.0-mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
Sodium Chloride, 0.9%: The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
FG0004 subjects
FG0013 subjects
FG0027 subjects
FG0033 subjects
FG00410 subjects
FG00510 subjects
FG0060 subjectsGroups 7A,B, 8A,B, and 12A,B were not enrolled because of competing priorities and predicted difficulties enrolling into this group.
FG0070 subjectsGroups 7A,B, 8A,B, and 12A,B were not enrolled because of competing priorities and predicted difficulties enrolling into this group.
FG0088 subjects
FG00910 subjects
FG01010 subjects
FG0110 subjectsGroups 7A,B, 8A,B, and 12A,B were not enrolled because of competing priorities and predicted difficulties enrolling into this group.
FG0127 subjects
FG0137 subjects
FG0142 subjects
COMPLETED
FG0004 subjects
FG0012 subjects
FG0026 subjects
FG0033 subjects
FG0049 subjects
FG00510 subjects
FG0060 subjects
FG0070 subjects
FG0088 subjects
FG00910 subjects
FG01010 subjects
FG0110 subjects
FG0127 subjects
FG0137 subjects
FG0142 subjects
NOT COMPLETED
FG0000 subjects
FG0011 subjects
FG0021 subjects
FG0030 subjects
FG0041 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
Type
Comment
Reasons
Physician Decision
FG0000 subjects
FG0011 subjects
FG0020 subjects
FG0030 subjects
FG0040 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0120 subjects
FG0130 subjects
FG0140 subjects
Protocol Violation
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
The Safety Analysis population for the study includes all participants who received one dose of vaccine.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
BG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
BG002
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
BG003
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
BG004
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
BG005
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
BG006
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
BG007
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
BG008
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
BG009
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
BG010
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
BG011
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
BG012
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG0004
BG0013
BG0027
BG0033
BG00410
BG00510
BG0068
BG00710
BG00810
BG0097
BG0107
BG0112
BG01281
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Standard Deviation
years
Title
Denominators
Categories
Title
Measurements
BG00032.5± 8.9
BG00123.3± 8.4
BG00245.4± 11.7
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG0000
BG0010
BG002
Ethnicity (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Hispanic or Latino
BG0000
BG0011
BG002
Race (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
American Indian or Alaska Native
BG0000
BG0010
BG002
Previous COVID-19 Infection
Count of Participants
Participants
Title
Denominators
Categories
Previous infection
Title
Measurements
BG0000
BG0010
BG002
BMI
Mean
Standard Deviation
kg/m^2
Title
Denominators
Categories
Title
Measurements
BG00025.23± 3.48
BG00121.03± 3.18
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)
Number of participants that experienced any NOCMCs during the course of the study
The Safety Analysis population for the study includes all participants who received one dose of vaccine.
Posted
Count of Participants
Participants
Day 1 to study completion through up to 1 year post last dose
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
OG002
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG003
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG005
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG006
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG007
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG008
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG009
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG010
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG011
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG0004
OG0013
OG0027
OG003
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0022
OG003
Primary
Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)
Number of participants that experienced any PIMMCs during the course of the study
The Safety Analysis population for the study includes all participants who received one dose of vaccine.
Posted
Count of Participants
Participants
Day 1 to study completion through up to 1 year post last dose
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
OG002
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG003
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Primary
Frequency of Any Medically Attended Adverse Events (MAAEs)
Number of participants that experienced any MAAEs during the course of the study
The Safety Analysis population for the study includes all participants who received one dose of vaccine.
Posted
Count of Participants
Participants
Day 1 to study completion through up to 1 year post last dose
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
OG002
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG003
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Primary
Frequency of Any Laboratory AE
Number of participants that experienced any laboratory AE
The Safety Analysis population for the study includes all participants who received one dose of vaccine.
Posted
Count of Participants
Participants
Through 7 days post each study vaccination
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
OG002
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG003
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Primary
Frequency of Any Serious Adverse Events (SAEs)
The number of participants that experience any SAEs from Day 1 to study completion. An AE or suspected adverse reaction is considered serious if, in the view of either the participating site PI or appropriate sub-investigator or the sponsor, it results in: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
The Safety Analysis population for the study includes all participants who received one dose of vaccine.
Posted
Count of Participants
Participants
Day 1 to study completion through up to 1 year post last dose
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
OG002
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
Primary
Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)
Number of participants who experienced any systemic solicited AEs through 7 days post any vaccination. Systemic events include: fatigue, headache, myalgia, arthralgia, nausea, chills and fever.
The Safety Analysis population for the study includes all participants who received one dose of vaccine.
Posted
Count of Participants
Participants
Day 1 through Day 8 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and through 7 days post any vaccination for Groups 1, 3A, 3b and 4.
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
OG002
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG003
Primary
Frequency of Local Solicited Reactogenicity Adverse Events (AEs)
Number of participants who experienced any local solicited AEs through 7 days post any vaccination. Local events include: pain at injection site, erythema, and induration.
The Safety Analysis population for the study includes all participants who received one dose of vaccine.
Posted
Count of Participants
Participants
Day 1 through Day 8 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and through 7 days post any vaccination for Groups 1, 3A, 3b and 4.
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
OG002
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG003
Primary
Frequency of Any Unsolicited Adverse Events (AEs)
Number of participants who experienced any unsolicited AEs through 28 days post vaccination
The Safety Analysis population for the study includes all participants who received one dose of vaccine.
Posted
Count of Participants
Participants
Day 1 through Day 29 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and 28 days post any vaccination for Groups 1, 3A, 3b and 4.
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
OG002
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG003
Stage 1 (Naïve) Group 4
Secondary
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 29 Post Vaccination 1, Day 57 Post Vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Secondary
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 57 Post Vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Secondary
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Secondary
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Secondary
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 169 Post Vac 1 (85 Days Post Vac 2), Day 265 Post Vac 1 (181 Days Post Vac 2), Day 450 Post Vac 1 (366 Days Post Vac 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Secondary
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Secondary
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Secondary
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Secondary
Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Secondary
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2), Day 265 Post Vaccination 1 (181 Days Post Vaccination 2), Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A
Geometric Mean of RBD titer
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4
Geometric Mean of RBD titer
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean of RBD titer
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A
Geometric Mean of S-2P titer
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4
Geometric Mean of S-2P titer
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Geometric Mean of S-2P titer
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G S-2P
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percentage of participants
Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Secondary
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 1 and 3A
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1 S-2P
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percentage of participants
Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Secondary
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 1 and 3A
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5 S-2P
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percentage of participants
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G S-2P
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percentage of participants
Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Secondary
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.1 S-2P
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percentage of participants
Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Secondary
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 3B and 4
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.4/5 S-2P
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percentage of participants
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2), Day 265 Post Vaccination 1 (181 Days Post Vaccination 2), Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Secondary
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against D614G S-2P
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percentage of participants
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Secondary
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.1 S-2P
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percentage of participants
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Secondary
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.4/5 S-2P
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percentage of participants
Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Secondary
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
percentage of CD4+ T Cells
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4
Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
Secondary
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
Secondary
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
Secondary
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
Secondary
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
Secondary
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
Secondary
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
Secondary
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
Secondary
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
Secondary
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
Secondary
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15
Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154.
To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Number
95% Confidence Interval
percent of responders
Day 1 Pre-Vaccination, Day 15 Post Vaccination
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
Secondary
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A
Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A
Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A
Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A
Mean spot forming units per million of the S1 as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A
Mean spot forming units per million of the S2 as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A
Mean spot forming units per million of the Spike as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A
Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Secondary
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4
Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4
Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4
Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Secondary
Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4
Mean spot forming units per million of the S1 as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4
Mean spot forming units per million of the S2 as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4
Mean spot forming units per million of the Spike as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4
Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Secondary
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the S1 as measured by ELISpot.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the S2 as measured by ELISpot.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the Spike as measured by ELISpot.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Secondary
Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15
Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot.
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported.
Posted
Mean
95% Confidence Interval
SFU/million cells
Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Secondary
Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 1 arm consists of 3 participants as 1 participant did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 1 arm consists of 3 participants as 1 participant did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 1 arm consists of 3 participants as 1 participant did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 1 arm consists of 3 participants as 1 participant did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1
Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 1 arm consists of 3 participants as 1 participant did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 2 participants as 5 participants did not have any data reported for this outcome. The Group 4 arm consists of 2 participants as 1 participant did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 2 participants as 5 participants did not have any data reported for this outcome. The Group 4 arm consists of 2 participants as 1 participant did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 2 participants as 5 participants did not have any data reported for this outcome. The Group 4 arm consists of 2 participants as 1 participant did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 2 participants as 5 participants did not have any data reported for this outcome. The Group 4 arm consists of 2 participants as 1 participant did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1
Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 2 participants as 5 participants did not have any data reported for this outcome. The Group 4 arm consists of 2 participants as 1 participant did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 3 participants as 4 participants did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 3 participants as 4 participants did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 3 participants as 4 participants did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 3 participants as 4 participants did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 3 participants as 4 participants did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ID
Title
Description
OG000
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
Secondary
Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 5 and 6 arms consist of 3 participants as 7 participants in each arm did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
Units
Counts
Secondary
Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 5 and 6 arms consist of 3 participants as 7 participants in each arm did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
Units
Counts
Secondary
Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 5 and 6 arms consist of 3 participants as 7 participants in each arm did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
Units
Counts
Secondary
Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1
Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 5 and 6 arms consist of 3 participants as 7 participants in each arm did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
Units
Counts
Secondary
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1
Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 5 and 6 arms consist of 3 participants as 7 participants in each arm did not have any data reported for this outcome.
Posted
Mean
95% Confidence Interval
pg/mL
Day 29 Post Vaccination 1
ID
Title
Description
OG000
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
Units
Time Frame
Solicited AEs (i.e., reactogenicity) were collected from the time of each study vaccination through 7 days post each study vaccination. Unsolicited AEs of all severities were reported from the time of study product administration through 28 days post each vaccination.
Description
After 28 days post last vaccination through the end of study, only SAEs, AESIs (including PIMMCs, NOCMCs, and MAAEs), and AEs leading to withdrawal from the study were reported. All participants were followed through 12 months after their last study vaccination.
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Stage 1 (Naïve) Group 1
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10^10 vp ChAd-S followed by 30 µg SAM-S.
0
4
0
4
4
4
EG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
0
3
0
3
3
3
EG002
Stage 1 (Naïve) Group 3B
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.
0
7
0
7
7
7
EG003
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
0
3
0
3
3
3
EG004
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
0
10
0
10
10
10
EG005
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
0
10
0
10
10
10
EG006
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
0
8
0
8
8
8
EG007
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
0
10
0
10
10
10
EG008
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
0
10
0
10
10
10
EG009
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
0
7
0
7
7
7
EG010
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
0
7
0
7
7
7
EG011
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
0
2
0
2
2
2
Serious Adverse Events
Not provided
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Nausea
Gastrointestinal disorders
MedDRA 26.0
Systematic Assessment
EG0001 events1 affected4 at risk
EG0015 events3 affected3 at risk
EG0026 events5 affected7 at risk
EG0032 events1 affected3 at risk
EG0043 events3 affected10 at risk
EG0052 events2 affected10 at risk
EG0063 events3 affected8 at risk
EG0072 events2 affected10 at risk
EG0083 events3 affected10 at risk
EG0090 events0 affected7 at risk
EG0101 events1 affected7 at risk
EG0111 events1 affected2 at risk
Diarrhoea
Gastrointestinal disorders
MedDRA 26.0
Systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Chills
General disorders
MedDRA 26.0
Systematic Assessment
EG0006 events4 affected4 at risk
EG0015 events3 affected3 at risk
EG00211 events7 affected7 at risk
EG003
Fatigue
General disorders
MedDRA 26.0
Systematic Assessment
EG0007 events4 affected4 at risk
EG0013 events2 affected3 at risk
EG00212 events7 affected7 at risk
EG003
Injection site pain
General disorders
MedDRA 26.0
Systematic Assessment
EG0006 events4 affected4 at risk
EG0013 events2 affected3 at risk
EG00212 events7 affected7 at risk
EG003
Malaise
General disorders
MedDRA 26.0
Systematic Assessment
EG0006 events4 affected4 at risk
EG0015 events3 affected3 at risk
EG00213 events7 affected7 at risk
EG003
Pyrexia
General disorders
MedDRA 26.0
Systematic Assessment
EG0002 events2 affected4 at risk
EG0014 events3 affected3 at risk
EG00210 events7 affected7 at risk
EG003
Vaccination site erythema
General disorders
MedDRA 26.0
Systematic Assessment
EG0000 events0 affected4 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Vaccination site induration
General disorders
MedDRA 26.0
Systematic Assessment
EG0002 events2 affected4 at risk
EG0011 events1 affected3 at risk
EG0022 events2 affected7 at risk
EG003
Vaccination site pain
General disorders
MedDRA 26.0
Systematic Assessment
EG0008 events4 affected4 at risk
EG0014 events3 affected3 at risk
EG00213 events7 affected7 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Systematic Assessment
EG0003 events2 affected4 at risk
EG0012 events2 affected3 at risk
EG0024 events3 affected7 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Systematic Assessment
EG0004 events3 affected4 at risk
EG0015 events3 affected3 at risk
EG0028 events6 affected7 at risk
EG003
Headache
Nervous system disorders
MedDRA 26.0
Systematic Assessment
EG0005 events3 affected4 at risk
EG0015 events3 affected3 at risk
EG00211 events6 affected7 at risk
EG003
Lymphadenopathy
Blood and lymphatic system disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Lymphopenia
Blood and lymphatic system disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Neutropenia
Blood and lymphatic system disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Bradycardia
Cardiac disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Coronary artery disease
Cardiac disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Palpitations
Cardiac disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Tachycardia
Cardiac disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Ear discomfort
Ear and labyrinth disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Ear pain
Ear and labyrinth disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Tinnitus
Ear and labyrinth disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Conjunctival hyperaemia
Eye disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Vitreous floaters
Eye disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Abdominal tenderness
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Dry mouth
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Eosinophilic oesophagitis
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Gastrooesophageal reflux disease
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Gingival pain
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Haematochezia
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Toothache
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0011 events1 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Fatigue
General disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Injection site bruising
General disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Injection site haemorrhage
General disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Malaise
General disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Pyrexia
General disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Swelling face
General disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Hypersensitivity
Immune system disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
COVID-19
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0001 events1 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Gastroenteritis
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Herpes dermatitis
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Herpes zoster
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Myringitis
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Sinusitis
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Subcutaneous abscess
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Upper respiratory tract infection
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Viral infection
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Vulvovaginal mycotic infection
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Contusion
Injury, poisoning and procedural complications
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Joint Injury
Injury, poisoning and procedural complications
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Limb Injury
Injury, poisoning and procedural complications
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Meniscus injury
Injury, poisoning and procedural complications
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Muscle strain
Injury, poisoning and procedural complications
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Pelvic fracture
Injury, poisoning and procedural complications
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Skin laceration
Injury, poisoning and procedural complications
MedDRA 26.0
Non-systematic Assessment
EG0001 events1 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Tendon injury
Injury, poisoning and procedural complications
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Blood cholesterol increased
Investigations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Blood creatinine increased
Investigations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Blood pressure diastolic increased
Investigations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Blood pressure systolic increased
Investigations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Cardiac murmur
Investigations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Dehydration
Metabolism and nutrition disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0011 events1 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Hyperlipidaemia
Metabolism and nutrition disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Type 2 diabetes mellitus
Metabolism and nutrition disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Flank pain
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Muscle spasms
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Neck pain
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Osteoarthritis
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Periarthritis
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0021 events1 affected7 at risk
EG003
Tendonitis
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Trigger finger
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Skin papilloma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected4 at risk
EG0010 events0 affected3 at risk
EG0020 events0 affected7 at risk
EG003
Uterine leiomyoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG005
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG006
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG007
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG008
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG009
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG010
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG011
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG0004
OG0013
OG0027
OG0033
OG00410
OG00510
OG0068
OG00710
OG00810
OG0097
OG0107
OG0112
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0021
OG0030
OG0040
OG0052
OG0060
OG0070
OG0080
OG0090
OG0100
OG0110
OG004
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG005
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG006
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG007
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG008
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG009
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG010
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG011
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG0004
OG0013
OG0027
OG0033
OG00410
OG00510
OG0068
OG00710
OG00810
OG0097
OG0107
OG0112
Title
Denominators
Categories
Title
Measurements
OG0000
OG0011
OG0024
OG0031
OG0044
OG0054
OG0063
OG0073
OG0085
OG0093
OG0101
OG0110
OG004
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG005
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG006
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG007
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG008
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG009
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG010
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG011
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG0004
OG0013
OG0027
OG0033
OG00410
OG00510
OG0068
OG00710
OG00810
OG0097
OG0107
OG0112
Title
Denominators
Categories
Title
Measurements
OG0004
OG0013
OG0027
OG0033
OG0048
OG0058
OG0067
OG0078
OG00810
OG0096
OG0105
OG0110
OG003
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG005
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG006
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG007
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG008
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG009
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG010
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG011
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG0004
OG0013
OG0027
OG0033
OG00410
OG00510
OG0068
OG00710
OG00810
OG0097
OG0107
OG0112
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0040
OG0050
OG0060
OG0070
OG0080
OG0090
OG0100
OG0110
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG005
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG006
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG007
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG008
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG009
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG010
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG011
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG0004
OG0013
OG0027
OG0033
OG00410
OG00510
OG0068
OG00710
OG00810
OG0097
OG0107
OG0112
Title
Denominators
Categories
Title
Measurements
OG0004
OG0013
OG0027
OG0033
OG00410
OG00510
OG0068
OG00710
OG00810
OG0093
OG0105
OG0112
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG005
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG006
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG007
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG008
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG009
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG010
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG011
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG0004
OG0013
OG0027
OG0033
OG00410
OG00510
OG0068
OG00710
OG00810
OG0097
OG0107
OG0112
Title
Denominators
Categories
Title
Measurements
OG0004
OG0013
OG0027
OG0033
OG00410
OG0058
OG0065
OG0078
OG0089
OG0091
OG0102
OG0111
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG005
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG006
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG007
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG008
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG009
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG010
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG011
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG0004
OG0013
OG0027
OG0033
OG00410
OG00510
OG0068
OG00710
OG00810
OG0097
OG0107
OG0112
Title
Denominators
Categories
Title
Measurements
OG0001
OG0012
OG0026
OG0033
OG00410
OG0058
OG0067
OG0077
OG0088
OG0096
OG0105
OG0112
Counts
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00011.90(3.29 to 43.05)
OG0014.06(0.19 to 87.32)
Day 57 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00072.48(26.51 to 198.20)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00012.27(5.47 to 27.52)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000573.77(185.04 to 1779.08)
OG001
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 57 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
OG001NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
OG0004
OG0013
Title
Denominators
Categories
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
OG001NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0001.00(NA to NA)95% CI was not estimable because all values were equal.
OG0019.09(1.61 to 51.40)
Day 57 Post Vaccination 1
ParticipantsOG0003
ParticipantsOG0013
Title
Measurements
OG0001.00(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0001.00(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0001.18(0.77 to 1.80)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0001.35(0.62 to 2.92)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0001.00(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000258.71(69.53 to 962.60)
OG001
Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG00042.59(5.68 to 319.58)
OG001
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0011
Title
Measurements
OG0001.00(NA to NA)95% CI was not estimable because all values were equal.
OG0011.00(NA to NA)95% CI was not estimable because all values were equal.
Day 57 Post Vaccination 1
ParticipantsOG0000
ParticipantsOG0011
Title
Measurements
OG0011.00(NA to NA)95% CI was not estimable because all values were equal.
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0011
Title
Measurements
OG0001.00(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0011
Title
Measurements
OG0001.00(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0011
Title
Measurements
OG0001.00(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0011
Title
Measurements
OG0001.93(0.41 to 9.03)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0011
Title
Measurements
OG00028.25(1.01 to 787.95)
OG001
Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0011
Title
Measurements
OG00011.46(0.27 to 492.52)
OG001
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG000NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
OG001NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 15 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0003.33(1.62 to 6.85)
OG0013.05(1.20 to 7.80)
OG0026.64(2.00 to 22.00)
OG003
Day 29 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 366 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 15 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0004.81(1.76 to 13.14)
OG0014.95(1.64 to 14.94)
OG0026.49(2.02 to 20.85)
OG003
Day 29 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 366 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 15 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0004.32(1.89 to 9.90)
OG0013.47(1.42 to 8.498)
OG0023.38(1.03 to 11.09)
OG003
Day 29 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 366 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG0015.0000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00059.4991(16.4477 to 215.2359)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000362.4094(132.5303 to 991.0228)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00061.3577(27.3553 to 137.6248)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0002868.8374(925.2210 to 8895.4181)
OG001
OG0004
OG0013
Title
Denominators
Categories
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00012.8238(4.2634 to 38.5724)
OG0015.0000(NA to NA)95% CI was not estimable because all values were equal.
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0001611.5218(162.1484 to 16016.2079)
OG001
OG0004
OG0013
Title
Denominators
Categories
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00016.3926(3.3992 to 79.0522)
OG00123.6552(3.5475 to 157.7338)
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0001345.8006(316.0828 to 5730.0774)
OG001
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG0015.0000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0013
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0005.8980(3.8574 to 9.0182)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0006.7531(3.1186 to 14.6237)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG0001293.5494(347.6573 to 4812.9874)
OG001
Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000212.9680(28.3847 to 1597.8817)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0011
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG0015.0000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0011
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 57 Post vaccination 1
ParticipantsOG0000
ParticipantsOG0011
Title
Measurements
OG0015.0000(NA to NA)95% CI was not estimable because all values were equal.
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0006.9420(3.9689 to 12.1423)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000120.5431(31.7334 to 457.8980)
OG001
Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG00084.8521(10.1712 to 707.8690)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0005.0000(NA to NA)95% CI was not estimable because all values were equal.
OG0015.0000(NA to NA)95% CI was not estimable because all values were equal.
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG00054.4021(13.4169 to 220.5873)
OG001
Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG00025.9869(2.1788 to 309.9511)
OG001
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000112.8328(74.9904 to 169.7717)
OG001405.4138(163.7296 to 1003.8523)
OG002102.8466(43.7058 to 242.0140)
OG003
Day 15 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 366 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00017.7942(10.4645 to 30.2577)
OG00133.4039(14.5993 to 76.4298)
OG00211.8710(7.2241 to 19.5068)
OG003
Day 15 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 366 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00012.5099(7.2840 to 21.4852)
OG00123.8982(11.1513 to 51.2159)
OG00245.8250(18.5629 to 113.1251)
OG003
Day 15 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 366 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG0001.4663(0.7258 to 2.9623)
OG0011.0000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG0004.0128(3.1921 to 5.0445)
OG001
Day 57 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG0005.2779(4.1399 to 6.7286)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0004.3994(3.3972 to 5.6972)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0006.5014(6.1134 to 6.9140)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0001.3894(0.9495 to 2.0331)
OG0011.8018(0.5013 to 6.4767)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0001.4036(0.9473 to 2.0797)
OG001
Day 57 Post Vaccination 1
ParticipantsOG0003
ParticipantsOG0013
Title
Measurements
OG0001.0000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0001.5076(0.9402 to 2.4175)
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0001.7037(1.0986 to 2.6421)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0001.5587(0.9254 to 2.6253)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0001.3002(0.8457 to 1.9989)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG0005.8158(5.2752 to 6.4118)
OG001
Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG0004.7615(3.7723 to 6.0101)
OG001
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0005.5864(5.2027 to 5.9984)
OG0016.1054(5.6569 to 6.5895)
OG0024.8833(4.4472 to 5.3623)
OG003
Day 15 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 366 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG0001.8212(0.9598 to 3.4558)
OG0011.0000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG0004.0618(3.4563 to 4.7734)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG0004.7630(3.8490 to 5.8940)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0003.5022(3.0395 to 4.0353)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0005.6119(4.8366 to 6.5116)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0001.2425(0.8811 to 1.7521)
OG0011.3426(0.3780 to 4.7688)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0002.2027(1.5276 to 3.1764)
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0013
Title
Measurements
OG0002.3213(0.3589 to 15.0141)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0002.0479(1.1017 to 3.8068)
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0002.3037(1.3810 to 3.8429)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0002.0917(1.0950 to 3.9956)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0002.6905(2.0117 to 3.5983)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG0005.1576(4.5793 to 5.8088)
OG001
Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG0004.5632(3.7534 to 5.5478)
OG001
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0005.2906(5.0215 to 5.5741)
OG0015.6841(5.2149 to 6.1955)
OG0024.5982(4.2377 to 4.9893)
OG003
Day 15 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 366 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000100(40 to 100)
OG00167(9 to 99)
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000100(40 to 100)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000100(40 to 100)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000100(40 to 100)
OG001
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00075(19 to 99)
OG0010(0 to 71)
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0000(0 to 60)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000100(40 to 100)
OG001
OG0004
OG0013
Title
Denominators
Categories
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00075(19 to 99)
OG001100(16 to 100)
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000100(40 to 100)
OG001
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG001100(29 to 100)
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0013
Title
Measurements
OG0000(0 to 71)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00017(1 to 64)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00017(1 to 64)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000100(48 to 100)
OG001
Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000100(48 to 100)
OG001
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0011
Title
Measurements
OG0000(0 to 60)
OG0010(0 to 98)
Day 57 Post vaccination 1
ParticipantsOG0000
ParticipantsOG0011
Title
Measurements
OG0010(0 to 98)
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00033(4 to 78)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000100(48 to 100)
OG001
Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000100(48 to 100)
OG001
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG0010(0 to 71)
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000100(48 to 100)
OG001
Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG00060(15 to 95)
OG001
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 15 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(69 to 100)
OG001100(69 to 100)
OG002100(63 to 100)
OG003
Day 29 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 366 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 15 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(69 to 100)
OG00190(55 to 99)
OG002100(63 to 100)
OG003
Day 29 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 366 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 15 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00090(55 to 99)
OG00190(55 to 99)
OG002100(63 to 100)
OG003
Day 29 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 366 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0000.033(-0.031 to 0.098)
OG0010.040(-0.109 to 0.190)
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0000.294(-0.098 to 0.687)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0000.216(0.006 to 0.427)
OG001
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0000.003(-0.004 to 0.011)
OG0010.001(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0000.024(-0.023 to 0.071)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0000.013(-0.026 to 0.053)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.007(0.002 to 0.012)
OG0010.012(-0.034 to 0.057)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.017(-0.003 to 0.037)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.011(-0.007 to 0.029)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.028(0.005 to 0.052)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.002(-0.001 to 0.005)
OG0010.015(-0.046 to 0.077)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.001(0.001 to 0.002)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.002(-0.001 to 0.005)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.003(0.000 to 0.005)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.003(0.001 to 0.005)
OG0010.001(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.002(-0.001 to 0.005)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.001(0.001 to 0.001)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.001(NA to NA)95% CI was not estimable because all values were equal.
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.001(NA to NA)95% CI was not estimable because all values were equal.
OG0010.007(-0.019 to 0.033)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.002(-0.000 to 0.004)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.006(-0.002 to 0.013)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.004(-0.001 to 0.009)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.004(0.001 to 0.007)
OG0010.001(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.002(0.000 to 0.005)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.001(0.000 to 0.003)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.002(-0.000 to 0.004)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.002(0.000 to 0.003)
OG0010.002(-0.001 to 0.004)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.001(0.000 to 0.003)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.001(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.002(-0.001 to 0.006)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.001(NA to NA)95% CI was not estimable because all values were equal.
OG0010.001(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.001(0.001 to 0.002)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.001(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.001(NA to NA)95% CI was not estimable because all values were equal.
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.001(NA to NA)95% CI was not estimable because all values were equal.
OG0010.003(-0.005 to 0.011)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.001(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.003(-0.001 to 0.007)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.001(0.000 to 0.003)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.002(0.000 to 0.004)
OG0010.001(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.001(0.001 to 0.002)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.001(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.001(0.001 to 0.001)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.001(NA to NA)95% CI was not estimable because all values were equal.
OG0010.004(-0.009 to 0.017)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000.004(-0.000 to 0.008)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.005(-0.002 to 0.011)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000.004(-0.003 to 0.012)
OG001
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.284(0.028 to 0.540)
OG0010.315(0.032 to 0.598)
OG0020.182(0.046 to 0.318)
OG003
Day 15 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.018(-0.018 to 0.053)
OG0010.005(0.000 to 0.009)
OG0020.018(-0.002 to 0.037)
OG003
Day 15 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.016(-0.003 to 0.034)
OG0010.011(-0.001 to 0.024)
OG0020.002(-0.000 to 0.005)
OG003
Day 15 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.004(-0.000 to 0.008)
OG0010.003(-0.000 to 0.006)
OG0020.036(-0.024 to 0.097)
OG003
Day 15 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.011(0.001 to 0.021)
OG0010.011(0.003 to 0.019)
OG0020.001(0.000 to 0.002)
OG003
Day 15 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.003(0.001 to 0.005)
OG0010.001(0.001 to 0.002)
OG0020.008(-0.006 to 0.023)
OG003
Day 15 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.003(-0.000 to 0.007)
OG0010.001(0.001 to 0.002)
OG0020.001(0.000 to 0.003)
OG003
Day 15 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.001(0.001 to 0.002)
OG0010.006(-0.003 to 0.015)
OG0020.012(-0.009 to 0.034)
OG003
Day 15 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.006(-0.002 to 0.014)
OG0010.005(-0.002 to 0.012)
OG0020.002(-0.000 to 0.004)
OG003
Day 15 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.002(0.000 to 0.004)
OG0010.002(0.000 to 0.003)
OG0020.020(-0.004 to 0.044)
OG003
Day 15 Post Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00025(1 to 81)
OG00150(1 to 99)
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00075(19 to 99)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00075(19 to 99)
OG001
OG001
Stage 1 (Naïve) Group 3A
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.
Units
Counts
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0000(0 to 60)
OG0010(0 to 84)
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG0000(0 to 60)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00025(1 to 81)
OG001
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG0010(0 to 71)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG0011(1 to 91)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG0010(0 to 71)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG0010(0 to 71)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG0010(0 to 71)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG0010(0 to 71)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG0010(0 to 71)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG0010(0 to 71)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG0010(0 to 71)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
OG001
Stage 1 (Naïve) Group 4
Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.
Units
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG0010(0 to 71)
Day 29 Post Vaccination 1
ParticipantsOG0007
ParticipantsOG0013
Title
Measurements
OG0000(0 to 41)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
Day 99 Post vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG0000(0 to 46)
OG001
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00070(35 to 93)
OG00180(44 to 97)
OG00263(24 to 91)
OG003
Day 15 Post-Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00010(1 to 45)
OG0010(0 to 31)
OG00213(1 to 53)
OG003
Day 15 Post-Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00010(1 to 45)
OG0010(0 to 31)
OG0020(0 to 37)
OG003
Day 15 Post-Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 31)
OG0010(0 to 31)
OG00213(1 to 53)
OG003
Day 15 Post-Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00010(1 to 45)
OG0010(0 to 31)
OG0020(0 to 37)
OG003
Day 15 Post-Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 31)
OG0010(0 to 31)
OG0020(0 to 37)
OG003
Day 15 Post-Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 31)
OG0010(0 to 31)
OG0020(0 to 37)
OG003
Day 15 Post-Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 31)
OG0010(0 to 31)
OG00213(1 to 53)
OG003
Day 15 Post-Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 31)
OG0010(0 to 34)
OG0020(0 to 37)
OG003
Day 15 Post-Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
OG001
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG002
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG0038
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 31)
OG0010(0 to 34)
OG00213(1 to 53)
OG003
Day 15 Post-Vaccination
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00018.125(8.180 to 28.070)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00042.500(-32.796 to 117.796)
OG001
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00016.875(10.908 to 22.842)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00029.375(12.381 to 46.369)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00017.500(9.544 to 25.456)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00021.667(-7.018 to 50.351)
OG001
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00017.500(9.544 to 25.456)
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00061.250(36.407 to 86.093)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000120.000(48.174 to 191.826)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00076.250(19.571 to 132.929)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG000257.500(-342.980 to 857.980)
OG001
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000131.875(-119.329 to 383.079)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000250.625(-187.616 to 688.866)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000140.625(-41.568 to 322.818)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG000525.833(-912.305 to 1963.972)
OG001
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00118.333(3.991 to 32.676)
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00060.625(12.407 to 108,843)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000123.750(74.224 to 173.276)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00074.375(22.775 to 125.975)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG000241.667(-291.170 to 774.503)
OG001
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00020.625(10.163 to 31.087)
OG00117.500(6.743 to 28.257)
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00016.875(10.908 to 22.842)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00036.875(9.052 to 64.698)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00049.375(-19.326 to 118.076)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00075.833(-67.723 to 219.389)
OG001
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000189.375(-64.772 to 443.522)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000370.625(-9.557 to 750.807)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000216.875(68.016 to 365.734)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG000775.000(-858.462 to 2408.462)
OG001
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00060.625(12.407 to 108.843)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000156.875(82.923 to 230.827)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000120.000(8.472 to 231.528)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG000317.500(-355.886 to 990.886)
OG001
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000250.000(-52.175 to 552.175)
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG000527.500(109.835 to 945.165)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG000336.875(194.760 to 478.990)
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG0001092.500(-594.520 to 2779.520)
OG001
Units
Counts
Participants
OG0004
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 57 Post vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00026.250(5.579 to 46.921)
OG001
Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0012
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00054.167(-69.157 to 177.491)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00016.250(13.037 to 19.463)
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00016.250(13.037 to 19.463)
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 85 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG00018.500(8.782 to 28.218)
OG001
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 85 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0012
Title
Measurements
OG00024.500(-1.876 to 50.876)
OG001
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00028.333(-0.005 to 56.671)
OG00119.167(1.239 to 37.094)
Day 29 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00037.917(-16.015 to 91.848)
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00040.000(-29.155 to 109.155)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00018.750(6.816 to 30.684)
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00021.875(-0.004 to 43.754)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00019.375(11.174 to 27.576)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00017.083(11.728 to 22.439)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0012
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00029.167(8.134 to 50.199)
OG00120.000(-1.513 to 41.513)
Day 29 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00034.167(-4.057 to 72.391)
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00025.833(-2.171 to 53.837)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00031.875(-1.625 to 65.375)
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00022.500(8.342 to 36.658)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00033.125(-1.153 to 67.403)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00028.333(-2.248 to 58.914)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG00033.500(14.927 to 52.073)
OG001
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00028.750(2.318 to 55.182)
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 85 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00021.250(1.360 to 41.140)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00016.875(10.908 to 22.842)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00030.000(0.504 to 59.496)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000304.500(-478.516 to 1087.516)
OG001
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00032.500(-8.750 to 73.750)
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00021.667(6.038 to 37.296)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00020.000(10.256 to 29.744)
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00031.250(-2.739 to 65.239)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00021.875(-0.004 to 43.754)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00032.917(-5.621 to 71.455)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG00085.000(-51.935 to 221.935)
OG001
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00023.750(11.699 to 35.801)
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00019.167(1.239 to 37.094)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00017.500(9.544 to 25.456)
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00017.500(9.544 to 25.456)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00017.500(9.544 to 25.456)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00017.500(11.074 to 23.926)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG00023.000(5.523 to 40.477)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00027.917(6.129 to 49.705)
OG00120.000(-1.513 to 41.513)
Day 29 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00049.167(-21.264 to 119.598)
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00022.500(-9.770 to 54.770)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00026.875(-10.917 to 64.667)
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00025.625(5.504 to 45.746)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00033.125(-1.153 to 67.403)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00044.583(-5.097 to 94.263)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000324.500(-469.444 to 1118.444)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00041.250(-17.690 to 100.190)
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 85 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00031.250(-2.739 to 65.239)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00021.875(-0.004 to 43.754)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00035.417(-17.066 to 87.899)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG00090.500(-75.948 to 256.948)
OG001
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00027.917(6.129 to 49.705)
OG00120.000(-1.513 to 41.513)
Day 29 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00077.917(-57.135 to 212.968)
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00022.500(-9.770 to 54.770)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00026.875(-10.917 to 64.667)
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00045.625(2.734 to 88.516)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00040.000(11.498 to 68.502)
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00067.500(-35.737 to 170.737)
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0013
Title
Measurements
OG000406.000(-375.313 to 1187.313)
OG001
Units
Counts
Participants
OG0007
OG0013
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00026.250(-2.669 to 55.169)
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
Day 29 Post Vaccination 1
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00036.250(-18.375 to 90.875)
OG001
Day 57 Post vaccination 1
ParticipantsOG0003
ParticipantsOG0012
Title
Measurements
OG00040.000(-29.155 to 109.155)
OG001
Day 85 Post Vaccination 1
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00018.750(6.816 to 30.684)
OG001
Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00021.875(-0.004 to 43.754)
OG001
Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)
ParticipantsOG0004
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)
ParticipantsOG0006
ParticipantsOG0013
Title
Measurements
OG00015.000(NA to NA)95% CI was not estimable because all values were equal.
OG001
Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)
ParticipantsOG0005
ParticipantsOG0012
Title
Measurements
OG00031.000(-13.423 to 75.423)
OG001
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG0039
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00022.143(12.295 to 31.991)
OG00117.778(13.433 to 22.122)
OG00215.000(NA to NA)95% CI was not estimable because all values were equal.
OG003
Day 15 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post vaccination 1
ParticipantsOG0008
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
ParticipantsOG00310
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG0039
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00036.071(10.573 to 61.570)
OG00135.556(15.156 to 55.956)
OG00217.813(11.162 to 24.463)
OG003
Day 15 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post vaccination 1
ParticipantsOG0008
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
ParticipantsOG00310
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG0039
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00042.500(-7.269 to 92.269)
OG00128.611(1.433 to 55.790)
OG00220.938(9.882 to 31.993)
OG003
Day 15 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post vaccination 1
ParticipantsOG0008
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
ParticipantsOG00310
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000193.214(0.407 to 386.022)
OG001148.000(58.422 to 237.578)
OG002109.688(-26.303 to 245.678)
OG003
Day 15 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
ParticipantsOG00310
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000151.429(51.197 to 251.660)
OG001188.250(83.786 to 292.714)
OG002118.438(-12.291 to 249.166)
OG003
Day 15 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post vaccination 1
ParticipantsOG0008
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
ParticipantsOG00310
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000193.929(35.278 to 352.579)
OG001225.250(59.864 to 390.636)
OG002103.438(-8.943 to 215.818)
OG003
Day 15 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post vaccination 1
ParticipantsOG0008
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
ParticipantsOG00310
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00083.929(-7.196 to 175.053)
OG00191.500(19.770 to 163.230)
OG00244.688(18.334 to 71.041)
OG003
Day 15 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post vaccination 1
ParticipantsOG0008
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
ParticipantsOG00310
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000344.643(73.157 to 616.128)
OG001334.000(152.907 to 515.093)
OG002224.375(-43.540 to 492.290)
OG003
Day 15 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post vaccination 1
ParticipantsOG0008
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
ParticipantsOG00310
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000271.786(28.289 to 515.282)
OG001308.750(76.000 to 541.500)
OG002138.438(0.228 to 276.647)
OG003
Day 15 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post vaccination 1
ParticipantsOG0008
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
ParticipantsOG00310
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG0039
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000616.429(104.946 to 1127.911)
OG001641.250(239.386 to 1043.114)
OG002360.938(-38.143 to 760.018)
OG003
Day 15 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post vaccination 1
ParticipantsOG0008
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
ParticipantsOG00310
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.
OG003
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.
OG004
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.
OG005
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^10 vp ChAd-S-TCE.
OG006
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10^11 vp ChAd-S-TCE.
OG007
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15
Previously (>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10^11 vp ChAd-S-TCE.
Units
Counts
Participants
OG00010
OG00110
OG0028
OG00310
OG00410
OG0057
OG0067
OG0072
Title
Denominators
Categories
Day 1 Pre-Vaccination 1
ParticipantsOG0007
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG0039
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00072.143(-9.586 to 153.871)
OG00148.611(15.353 to 81.869)
OG00222.500(10.416 to 34.584)
OG003
Day 15 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 29 Post vaccination 1
ParticipantsOG0008
ParticipantsOG0019
ParticipantsOG0028
ParticipantsOG00310
Day 85 Post Vaccination 1
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG0028
ParticipantsOG00310
Day 181 Post Vaccination 1
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG0028
ParticipantsOG00310
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG00017.651(-26.698 to 62.000)
OG0015.290(-6.633 to 17.213)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG00010.427(-8.247 to 29.100)
OG00116.898(-28.172 to 61.967)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG00021.312(-44.758 to 87.382)
OG00117.151(-7.616 to 41.917)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG000109.721(-25.788 to 245.230)
OG00124.202(-41.440 to 89.845)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG00099.148(-120.489 to 318.785)
OG00118.059(-16.388 to 52.506)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG00087.137(-79.954 to 254.228)
OG00135.403(-58.048 to 128.854)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG00031.072(-31.944 to 94.089)
OG00117.899(-14.819 to 50.617)
S1
Title
Measurements
OG000208.869(-139.777 to 557.515)
OG00142.261(-56.755 to 141.278)
S2
Title
Measurements
OG000118.209(-108.211 to 344.629)
OG00153.302(-71.694 to 178.299)
Spike
Title
Measurements
OG000327.078(-246.801 to 900.957)
OG00195.564(-128.256 to 319.383)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG00049.390(-74.127 to 172.907)
OG00139.339(-20.521 to 99.198)
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0000.084(-0.113 to 0.281)
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0000.128(-0.079 to 0.335)
OG0010.082(-0.107 to 0.271)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.053(-0.013 to 0.119)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0000.492(-1.018 to 2.002)
OG0010.131(-0.270 to 0.532)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0000.176(-0.187 to 0.539)
OG0010.120(-0.081 to 0.321)
S1
Title
Measurements
OG0000.492(-1.018 to 2.002)
OG0010.131(-0.270 to 0.532)
S2
Title
Measurements
OG0000.176(-0.187 to 0.539)
OG0010.120(-0.081 to 0.321)
Spike
Title
Measurements
OG0000.656(-1.223 to 2.534)
OG0010.226(-0.441 to 0.862)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG0000.174(0.100 to 0.248)
OG0010.097(-0.069 to 0.264)
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0000.085(0.022 to 0.148)
OG0011.852(-5.255 to 8.985)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0000.761(-0.046 to 1.569)
OG0015.044(-16.357 to 26.445)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0000.387(-0.803 to 1.576)
OG0014.479(-13.349 to 22.307)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG0001.837(0.022 to 3.651)
OG00110.422(-32.497 to 53.340)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0001.557(-1.150 to 4.263)
OG0018.160(-24.018 to 40.338)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0000.740(-0.685 to 2.164)
OG0018.377(-27.366 to 44.121)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0000.486(-0.408 to 1.379)
OG0015.005(-15.816 to 25.827)
S1
Title
Measurements
OG0003.393(-0.379 to 7.166)
OG00118.558(-56.585 to 93.701)
S2
Title
Measurements
OG0001.225(-1.045 to 3.495)
OG00113.336(-43.328 to 70.000)
Spike
Title
Measurements
OG0004.618(-1.152 to 10.388)
OG00131.871(-99.986 to 163.728)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG0001.125(-0.392 to 2.641)
OG00111.304(-35.175 to 57.783)
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0005.252(-5.918 to 16.422)
OG0014.728(-2.353 to 11.790)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0002.597(-1.907 to 7.101)
OG0012.279(-0.856 to 5.413)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0002.124(-0.346 to 4.595)
OG0012.156(-0.451 to 4.763)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG0003.361(2.020 to 4.701)
OG0012.156(-0.451 to 4.763)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0006.043(-2.915 to 15.000)
OG0015.175(-4.396 to 14.746)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0002.342(0.606 to 4.078)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0003.736(-3.185 to 10.657)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
S1
Title
Measurements
OG0007.645(-0.619 to 15.909)
OG0016.298(-7.810 to 20.405)
S2
Title
Measurements
OG0003.324(-4.310 to 10.959)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
Spike
Title
Measurements
OG0009.936(8.286 to 11.586)
OG0016.298(-7.810 to 20.405)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG0007.390(-5.848 to 20.628)
OG0017.095(-8.863 to 23.054)
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0008.845(-10.475 to 28.166)
OG00112.990(-32.235 to 58.215)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0006.784(-2.998 to 16.565)
OG00127.390(-78.121 to 132.900)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0006.100(-10.727 to 22.927)
OG00118.547(-52.294 to 89.388)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG00017.145(0.386 to 33.904)
OG00172.302(-215.814 to 360.418)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG00018.845(-29.049 to 66.739)
OG00135.237(-99.111 to 169.585)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0009.712(-6.629 to 26.052)
OG00144.250(-134.450 to 222.950)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0007.229(-5.170 to 19.628)
OG00127.882(-82.377 to 138.140)
S1
Title
Measurements
OG00035.990(-28.290 to 100.270)
OG001107.539(-314.880 to 529.958)
S2
Title
Measurements
OG00016.941(-11.798 to 45.679)
OG00172.131(-216.817 to 361.080)
Spike
Title
Measurements
OG00052.931(-39.561 to 145.422)
OG001179.671(-531.688 to 891.029)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG00021.729(-24.130 to 67.588)
OG00158.926(-162.607 to 280.460)
OG0002
OG0012
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0005.246(-9.591 to 20.084)
OG00111.715(-3.949 to 27.378)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG000956.979(-11025.246 to 12939.203)
OG00110.155(0.651 to 19.659)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG00032.492(-46.226 to 111.210)
OG0019.801(-18.521 to 38.123)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG00041.112(-28.985 to 111.209)
OG00125.725(9.874 to 41.575)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0006.923(-32.972 to 46.817)
OG00112.611(-11.500 to 36.721)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG00017.987(-15.408 to 51.382)
OG00121.148(-109.252 to 151.549)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG00016.322(-0.333 to 32.976)
OG00116.493(4.263 to 28.723)
S1
Title
Measurements
OG00048.035(-61.957 to 158.026)
OG00138.335(30.076 to 46.594)
S2
Title
Measurements
OG00034.309(-15.741 to 84.358)
OG00137.641(-80.530 to 155.812)
Spike
Title
Measurements
OG00082.343(-77.698 to 242.384)
OG00175.976(-33.936 to 185.888)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG000994.717(-11081.063 to 13070.497)
OG00131.671(9.508 to 53.834)
OG0002
OG0012
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.299(-0.864 to 1.462)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG00036.585(-425.445 to 498.614)
OG0010.063(-0.255 to 0.381)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.186(-1.260 to 1.631)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.126(-0.995 to 1.248)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.601(0.182 to 1.020)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0000.082(-0.480 to 0.644)
OG0010.075(-0.389 to 0.538)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.260(-0.868 to 1.387)
S1
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.708(-1.074 to 2.490)
S2
Title
Measurements
OG0000.082(-0.480 to 0.644)
OG0010.315(-0.107 to 0.738)
Spike
Title
Measurements
OG0000.082(-0.480 to 0.644)
OG0011.024(-1.181 to 3.228)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG00036.585(-425.445 to 498.614)
OG0010.493(-2.014 to 2.999)
OG0002
OG0012
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG00012.384(-122.197 to 146.965)
OG0010.569(0.486 to 0.651)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG000329.048(-3803.325 to 4461.420)
OG0010.499(-2.315 to 3.313)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG00026.108(-263.975 to 316.190)
OG0010.657(-2.202 to 3.515)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG00022.599(-47.914 to 93.112)
OG0011.934(-4.778 to 8.646)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG00015.392(-121.365 to 152.149)
OG0011.158(-2.534 to 4.849)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG00030.663(-291.084 to 352.410)
OG0011.144(-0.819 to 3.107)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG00011.987(-100.279 to 124.252)
OG0010.522(-0.339 to 1.383)
S1
Title
Measurements
OG00037.991(-169.279 to 245.261)
OG0013.091(-7.312 to 13.494)
S2
Title
Measurements
OG00042.650(-391.363 to 476.662)
OG0011.666(0.563 to 2.768)
Spike
Title
Measurements
OG00080.641(-560.642 to 721.923)
OG0014.757(-6.748 to 16.262)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG000367.540(-4189.496 to 4924.575)
OG0011.724(-4.032 to 7.480)
OG0002
OG0012
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0003.460(-20.806 to 27.725)
OG0019.699(-11.108 to 30.505)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG000193.308(-2218.133 to 2604.748)
OG0014.304(0.825 to 7.782)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0003.897(-9.442 to 17.235)
OG00110.186(1.085 to 19.287)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG0003.953(-26.577 to 34.483)
OG00110.869(-7.695 to 29.432)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0004.015(-27.309 to 35.339)
OG0018.758(-34.291 to 51.806)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0004.833(-36.881 to 46.547)
OG0016.204(-18.376 to 30.784)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0004.609(-34.259 to 43.477)
OG00110.498(-14.232 to 35.227)
S1
Title
Measurements
OG0007.193(-64.508 to 78.894)
OG00119.626(-41.986 to 81.238)
S2
Title
Measurements
OG0008.667(-81.763 to 99.097)
OG00116.702(-32.608 to 66.011)
Spike
Title
Measurements
OG00015.085(-156.893 to 187.063)
OG00136.328(-74.594 to 147.250)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG000198.466(-2147.437 to 2544.368)
OG00124.188(-2.241 to 50.617)
OG0002
OG0012
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG000128.731(-1278.592 to 1536.055)
OG0013.194(-14.585 to 20.973)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0001861.230(-21502.562 to 25225.021)
OG0013.744(-11.380 to 18.867)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG000300.416(-3311.513 to 3912.345)
OG0013.433(1.766 to 5.101)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG000167.163(-1370.904 to 1705.230)
OG00110.697(-9.744 to 31.138)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG000145.340(-1474.361 to 1765.041)
OG0015.505(-1.083 to 12.093)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG000290.681(-3172.723 to 3754.084)
OG0016.443(-7.658 to 20.543)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG000123.765(-1132.231 to 1379.760)
OG0016.927(-39.381 to 53.235)
S1
Title
Measurements
OG000312.503(-2845.265 to 3470.271)
OG00116.202(-10.828 to 43.231)
S2
Title
Measurements
OG000414.445(-4304.954 to 5133.844)
OG00113.370(-47.039 to 73.778)
Spike
Title
Measurements
OG000726.948(-7150.219 to 8604.115)
OG00129.572(-57.866 to 117.009)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG0002290.337(-26092.667 to 30673.421)
OG00110.371(-20.864 to 41.606)
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG00013.754(-15.746 to 43.255)
OG00118.749(-24.999 to 62.498)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0005.648(-4.696 to 15.993)
OG00111.485(5.361 to 17.609)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG00015.310(-9.570 to 40.190)
OG00112.042(6.083 to 18.000)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG00024.703(-9.748 to 59.153)
OG00131.098(8.617 to 53.579)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG00024.621(-25.412 to 74.654)
OG00120.411(-10.602 to 51.424)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG00025.392(3.517 to 47.267)
OG00124.891(9.533 to 40.249)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG00032.809(7.250 to 58.367)
OG00131.035(-25.135 to 87.205)
S1
Title
Measurements
OG00049.324(-28.085 to 126.732)
OG00151.509(12.617 to 890.401)
S2
Title
Measurements
OG00058.201(39.136 to 77.265)
OG00155.926(6.785 to 105.067)
Spike
Title
Measurements
OG000107.524(18.334 to 196.714)
OG001107.435(85.905 to 128.965)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG00034.713(-9.368 to 78.793)
OG00142.267(4.842 to 79.709)
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0000.047(0.007 to 0.087)
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
S1
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
S2
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
Spike
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0000.808(-1.071 to 2.687)
OG0010.161(-0.037 to 0.359)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0001.208(-1.299 to 3.715)
OG0010.156(-0.215 to 0.528)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0001.072(-1.499 to 3.643)
OG0010.070(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG0006.466(-6.123 to 19.054)
OG0012.167(-0.821 to 5.156)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0003.250(-6.541 to 13.041)
OG0010.391(-0.509 to 1.290)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0002.050(-3.687 to 7.787)
OG0011.064(-0.516 to 2.644)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0001.538(-2.160 to 5.236)
OG0010.341(-0.123 to 0.806)
S1
Title
Measurements
OG0009.715(-12.623 to 32.053)
OG0012.534(-1.035 to 6.104)
S2
Title
Measurements
OG0003.565(-5.910 to 13.040)
OG0011.361(-0.812 to 3.534)
Spike
Title
Measurements
OG00013.257(-18.587 to 45.101)
OG0013.895(-1.769 to 9.559)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG0003.042(-4.085 to 10.168)
OG0010.271(-0.346 to 0.887)
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0003.796(-5.868 to 13.461)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0004.089(-1.868 to 10.046)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0003.404(-1.897 to 8.704)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG0001.550(NA to NA)95% CI was not estimable because all values were equal.
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0005.534(-3.050 to 14.117)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0001.990(0.097 to 3.882)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0003.485(-0.679 to 7.649)
OG0011.880(0.459 to 3.302)
S1
Title
Measurements
OG0005.534(-3.050 to 14.117)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
S2
Title
Measurements
OG0003.485(-0.679 to 7.649)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
Spike
Title
Measurements
OG0008.502(-6.458 to 23.462)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG0008.764(-12.848 to 30.376)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0005.400(2.225 to 8.575)
OG0013.213(1.238 to 5.188)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0007.971(-0.802 to 16.744)
OG0014.853(-4.970 to 14.677)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0006.162(3.692 to 8.633)
OG0011.989(-1.134 to 5.113)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG00018.952(8.464 to 29.440)
OG00113.546(1.295 to 25.796)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0008.549(2.027 to 15.072)
OG0015.384(-1.534 to 12.302)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0009.284(5.387 to 13.182)
OG0017.804(-2.993 to 18.601)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0007.486(2.208 to 12.763)
OG0015.214(2.196 to 8.232)
S1
Title
Measurements
OG00027.501(23.446 to 31.556)
OG00118.930(-0.212 to 38.071)
S2
Title
Measurements
OG00016.770(7.628 to 25.911)
OG00113.018(2.007 to 24.029)
Spike
Title
Measurements
OG00044.271(38.797 to 49.745)
OG00131.948(1.796 to 62.099)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG00019.533(8.308 to 30.759)
OG00110.056(-4.766 to 24.877)
Participants
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG00015.533(-7.734 to 38.800)
OG00115.847(-15.260 to 46.954)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG00016.116(-35.309 to 67.540)
OG00119.297(9.430 to 29.164)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG00026.168(-21.150 to 73.487)
OG00115.559(-12.381 to 43.500)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG000129.978(-26.833 to 280.788)
OG001732.268(-1781.612 to 3246.148)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG00087.681(40.903 to 134.459)
OG001755.178(-1720.997 to 3231.353)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG00091.627(41.985 to 141.269)
OG001727.250(-1796.013 to 3250.513)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG00051.847(-6.682 to 110.376)
OG001689.798(-1913.803 to 3293.398)
S1
Title
Measurements
OG000214.659(15.434 to 413.883)
OG0011487.446(-3499.827 to 6474.719)
S2
Title
Measurements
OG000143.474(130.879 to 156.068)
OG0011417.047(-3709.505 to 6543.599)
Spike
Title
Measurements
OG000358.132(152.738 to 563.527)
OG0012904.493(-7203.839 to 13012.825)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG00057.817(-54.718 to 170.351)
OG00150.703(2.394 to 99.013)
Participants
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.047(0.007 to 0.087)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0000.109(-0.129 to 0.347)
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG0000.059(-0.031 to 0.149)
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0000.076(-0.007 to 0.158)
OG0010.052(-0.009 to 0.113)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.056(-0.023 to 0.135)
S1
Title
Measurements
OG0000.097(0.080 to 0.114)
OG0010.052(-0.009 to 0.113)
S2
Title
Measurements
OG0000.038(NA to NA)95% CI was not estimable because all values were equal.
OG0010.056(-0.023 to 0.135)
Spike
Title
Measurements
OG0000.097(0.080 to 0.114)
OG0010.071(-0.001 to 0.142)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG0000.098(-0.160 to 0.356)
OG0010.038(NA to NA)95% CI was not estimable because all values were equal.
Participants
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0000.438(-1.145 to 2.021)
OG0011.264(-1.181 to 3.709)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0001.124(-1.271 to 3.518)
OG0012.151(-2.251 to 6.552)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0000.778(-1.270 to 2.826)
OG0012.972(-3.942 to 9.887)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG0006.628(-4.934 to 18.190)
OG00121.391(-15.156 to 57.939)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0001.533(-1.047 to 4.112)
OG0015.901(-4.033 to 15.834)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0001.541(-2.614 to 5.695)
OG0015.602(-3.234 to 14.438)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0001.021(-1.755 to 3.796)
OG0013.856(-0.787 to 8.500)
S1
Title
Measurements
OG0008.160(-5.656 to 21.976)
OG00127.292(-18.886 to 73.469)
S2
Title
Measurements
OG0002.561(-4.259 to 9.382)
OG0019.458(-2.042 to 20.959)
Spike
Title
Measurements
OG00010.722(-9.787 to 31.230)
OG00136.750(-20.243 to 93.743)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG0002.269(-3.824 to 8.363)
OG0016.348(-7.359 to 20.055)
Participants
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0003.205(-0.359 to 6.768)
OG0013.558(-2.315 to 9.431)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG0002.692(-2.223 to 7.607)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0002.622(0.315 to 4.928)
OG0011.909(0.365 to 3.453)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG0002.935(-3.024 to 8.893)
OG0011.550(NA to NA)95% CI was not estimable because all values were equal.
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG0002.716(0.125 to 5.307)
OG0013.376(-0.623 to 7.375)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG0002.072(-0.175 to 4.320)
OG0011.990(0.097 to 3.882)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG0001.938(0.270 to 3.605)
OG0012.757(-2.437 to 7.952)
S1
Title
Measurements
OG0003.605(-1.556 to 8.766)
OG0013.376(-0.623 to 7.375)
S2
Title
Measurements
OG0002.072(-0.175 to 4.320)
OG0012.757(-2.437 to 7.952)
Spike
Title
Measurements
OG0004.644(-4.684 to 13.972)
OG0015.100(-4.414 to 14.613)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG0006.452(0.977 to 11.927)
OG0013.088(-3.529 to 9.705)
Counts
Participants
OG0003
OG0013
Title
Denominators
Categories
15mer OLPs Spanning Membrane Frame
Title
Measurements
OG0007.161(-1.168 to 15.490)
OG00111.752(-9.290 to 32.793)
15mer OLPa Spanning Nucleocapsid Frame
Title
Measurements
OG00010.909(-0.194 to 22.012)
OG00120.224(-16.584 to 57.032)
15mer OLPs spanning Open Reading Frame 3a
Title
Measurements
OG0007.423(-5.791 to 20.636)
OG00116.296(-12.389 to 44.982)
Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools
Title
Measurements
OG00030.201(8.447 to 51.954)
OG001209.438(-72.520 to 491.395)
Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools
Title
Measurements
OG00012.700(-1.047 to 26.446)
OG00196.215(-107.586 to 300.016)
Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools
Title
Measurements
OG00014.317(3.558 to 25.076)
OG00168.809(-58.408 to 196.027)
Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools
Title
Measurements
OG00010.754(-4.612 to 26.120)
OG00171.193(-84.607 to 226.993)
S1
Title
Measurements
OG00042.900(7.621 to 78.180)
OG001305.653(-149.208 to 760.514)
S2
Title
Measurements
OG00025.071(-0.986 to 51.128)
OG001140.002(-142.724 to 422.728)
Spike
Title
Measurements
OG00067.971(6.724 to 129.219)
OG001445.655(-252.526 to 1143.836)
15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a
Title
Measurements
OG00025.493(-6.663 to 57.649)
OG00148.272(-37.362 to 133.905)
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
5 events
3 affected
3 at risk
EG0045 events5 affected10 at risk
EG0057 events7 affected10 at risk
EG0063 events3 affected8 at risk
EG0075 events5 affected10 at risk
EG0087 events7 affected10 at risk
EG0090 events0 affected7 at risk
EG0101 events1 affected7 at risk
EG0112 events2 affected2 at risk
6 events
3 affected
3 at risk
EG0049 events9 affected10 at risk
EG0058 events8 affected10 at risk
EG0067 events7 affected8 at risk
EG0079 events9 affected10 at risk
EG0088 events8 affected10 at risk
EG0093 events3 affected7 at risk
EG0104 events4 affected7 at risk
EG0112 events2 affected2 at risk
5 events
3 affected
3 at risk
EG0049 events9 affected10 at risk
EG00510 events10 affected10 at risk
EG0067 events7 affected8 at risk
EG0076 events6 affected10 at risk
EG00810 events10 affected10 at risk
EG0091 events1 affected7 at risk
EG0104 events4 affected7 at risk
EG0112 events2 affected2 at risk
6 events
3 affected
3 at risk
EG0045 events5 affected10 at risk
EG0055 events5 affected10 at risk
EG0066 events6 affected8 at risk
EG0075 events5 affected10 at risk
EG0088 events8 affected10 at risk
EG0092 events2 affected7 at risk
EG0103 events3 affected7 at risk
EG0112 events2 affected2 at risk
5 events
3 affected
3 at risk
EG0041 events1 affected10 at risk
EG0054 events4 affected10 at risk
EG0060 events0 affected8 at risk
EG0072 events2 affected10 at risk
EG0082 events2 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0112 events2 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
1 events
1 affected
3 at risk
EG0041 events1 affected10 at risk
EG0052 events2 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0083 events3 affected10 at risk
EG0090 events0 affected7 at risk
EG0102 events2 affected7 at risk
EG0110 events0 affected2 at risk
6 events
3 affected
3 at risk
EG00410 events10 affected10 at risk
EG0058 events8 affected10 at risk
EG0065 events5 affected8 at risk
EG0078 events8 affected10 at risk
EG0089 events9 affected10 at risk
EG0091 events1 affected7 at risk
EG0102 events2 affected7 at risk
EG0111 events1 affected2 at risk
1 events
1 affected
3 at risk
EG0042 events2 affected10 at risk
EG0052 events2 affected10 at risk
EG0061 events1 affected8 at risk
EG0074 events4 affected10 at risk
EG0085 events5 affected10 at risk
EG0090 events0 affected7 at risk
EG0102 events2 affected7 at risk
EG0111 events1 affected2 at risk
5 events
3 affected
3 at risk
EG0045 events5 affected10 at risk
EG0055 events5 affected10 at risk
EG0066 events6 affected8 at risk
EG0076 events6 affected10 at risk
EG0088 events8 affected10 at risk
EG0091 events1 affected7 at risk
EG0104 events4 affected7 at risk
EG0112 events2 affected2 at risk
6 events
3 affected
3 at risk
EG0046 events6 affected10 at risk
EG0058 events8 affected10 at risk
EG0064 events4 affected8 at risk
EG0078 events8 affected10 at risk
EG0087 events7 affected10 at risk
EG0091 events1 affected7 at risk
EG0104 events4 affected7 at risk
EG0111 events1 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0101 events1 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0101 events1 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
1 events
1 affected
3 at risk
EG0041 events1 affected10 at risk
EG0053 events2 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0111 events1 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
1 events
1 affected
3 at risk
EG0042 events2 affected10 at risk
EG0051 events1 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0053 events3 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
1 events
1 affected
3 at risk
EG0045 events4 affected10 at risk
EG0055 events5 affected10 at risk
EG0062 events2 affected8 at risk
EG0075 events5 affected10 at risk
EG0081 events1 affected10 at risk
EG0096 events5 affected7 at risk
EG0104 events4 affected7 at risk
EG0111 events1 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0091 events1 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0042 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0042 events2 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0101 events1 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0091 events1 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0091 events1 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0072 events2 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0051 events1 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0111 events1 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0052 events2 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
1 events
1 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0081 events1 affected10 at risk
EG0091 events1 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0100 events0 affected7 at risk
EG0110 events0 affected2 at risk
0 events
0 affected
3 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected10 at risk
EG0080 events0 affected10 at risk
EG0090 events0 affected7 at risk
EG0102 events1 affected7 at risk
EG0110 events0 affected2 at risk
2.80
(0.03 to 235.59)
1.57
(0.01 to 477.31)
66.61
(7.44 to 596.29)
OG001NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
OG001NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
OG001NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
1.86
(0.48 to 7.13)
1.00
(NA to NA)
95% CI was not estimable because all values were equal.
23.98
(5.93 to 96.89)
17.21
(1.50 to 197.75)
9.98
(1.01 to 98.39)
298.33
(17.42 to 5110.28)
130.72
(1.46 to 11696.94)
1.00
(NA to NA)
95% CI was not estimable because all values were equal.
1.00
(NA to NA)
95% CI was not estimable because all values were equal.
2.40
(NA to NA)
95% CI was not estimable because all values were equal.
4.27
(NA to NA)
95% CI was not estimable because all values were equal.
42.65
(NA to NA)
95% CI was not estimable because all values were equal.
13.61
(NA to NA)
95% CI was not estimable because all values were equal.
OG001NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
OG001NA(NA to NA)Results were not estimable because pre-vaccination samples were not analyzed for this variant. This variant was not in circulation when the pre-vaccination visit samples were assayed and therefore never tested by the lab.
1.91
(1.19 to 3.05)
OG0042.03(1.01 to 4.07)
OG0052.15(0.65 to 7.08)
OG0061.52(0.81 to 2.83)
OG0076.06(0.00 to 5437456045.79)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0005.02(2.20 to 11.45)
OG0013.62(1.26 to 10.38)
OG0028.07(2.08 to 31.36)
OG0032.78(1.23 to 6.29)
OG0043.27(1.45 to 7.38)
OG0052.90(0.70 to 11.95)
OG0062.86(1.06 to 7.73)
OG0074.55(0.00 to 14716523.65)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0004.96(2.10 to 11.69)
OG0013.38(1.02 to 11.27)
OG00210.84(2.58 to 45.49)
OG0034.06(1.19 to 13.85)
OG0045.79(2.15 to 15.63)
OG00511.38(1.51 to 85.69)
OG0069.94(2.41 to 41.02)
OG0072.76(0.05 to 154.23)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00014.19(6.03 to 33.40)
OG0016.75(1.78 to 25.57)
OG00218.02(5.57 to 58.27)
OG0036.60(1.31 to 33.17)
OG0043.27(1.34 to 8.00)
OG00513.53(1.32 to 138.39)
OG0066.54(1.42 to 30.08)
OG0071.88(0.48 to 7.30)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00030.20(13.00 to 70.18)
OG00115.28(5.05 to 46.21)
OG00210.01(3.28 to 30.51)
OG0034.83(1.15 to 20.33)
OG0045.16(2.02 to 13.18)
OG00521.98(2.44 to 198.35)
OG0062.54(0.95 to 6.77)
OG0070.89(0.00 to 229.48)
1.74
(0.83 to 3.64)
OG0041.97(1.07 to 3.63)
OG0052.01(0.77 to 5.27)
OG0061.80(0.97 to 3.36)
OG0074.29(0.00 to 16082568.04)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0008.63(2.72 to 27.36)
OG0017.14(1.97 to 25.80)
OG0029.20(3.02 to 27.98)
OG0032.43(1.09 to 5.41)
OG0042.88(1.36 to 6.09)
OG0052.53(0.67 to 9.59)
OG0063.77(1.55 to 9.13)
OG0075.26(0.00 to 189185279.21)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0007.76(2.46 to 24.50)
OG0017.32(1.86 to 28.77)
OG00220.73(5.74 to 74.87)
OG0036.54(1.71 to 25.06)
OG0044.32(1.79 to 10.43)
OG00512.26(1.00 to 149.82)
OG00611.77(3.54 to 39.10)
OG0073.91(0.00 to 61879.16)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00018.53(6.50 to 52.83)
OG00113.39(2.83 to 63.29)
OG00256.02(12.24 to 256.46)
OG0038.76(1.53 to 50.19)
OG0043.35(1.51 to 7.43)
OG00515.55(1.30 to 186.51)
OG0066.12(1.52 to 24.60)
OG0073.12(0.50 to 19.57)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00086.85(41.81 to 180.39)
OG00174.37(26.44 to 209.18)
OG00240.58(10.60 to 155.32)
OG00311.83(2.32 to 60.39)
OG0049.95(2.73 to 36.30)
OG00544.10(6.07 to 320.15)
OG0064.70(0.95 to 23.29)
OG0071.46(0.00 to 23381.67)
1.01
(0.61 to 1.67)
OG0042.46(1.18 to 5.12)
OG0051.74(0.73 to 4.17)
OG0061.85(1.07 to 3.20)
OG0074.60(0.00 to 5401100.08)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0006.45(2.35 to 17.69)
OG0014.89(1.65 to 14.54)
OG0026.11(1.46 to 25.57)
OG0031.66(0.80 to 3.46)
OG0044.30(1.89 to 9.79)
OG0051.82(0.62 to 5.34)
OG0063.66(1.31 to 10.25)
OG0075.78(0.00 to 645374779.40)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0006.08(2.37 to 15.55)
OG0015.43(1.90 to 15.51)
OG0025.64(0.96 to 33.11)
OG0032.95(0.74 to 11.76)
OG0046.58(2.38 to 18.19)
OG00511.24(1.02 to 124.31)
OG00611.63(1.96 to 69.03)
OG0079.14(3.40 to 24.57)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00023.87(8.73 to 65.27)
OG00113.56(2.99 to 61.47)
OG00212.57(1.27 to 124.69)
OG0036.67(1.16 to 38.38)
OG0044.43(1.51 to 12.98)
OG00521.78(1.54 to 308.82)
OG0065.56(0.72 to 44.13)
OG00711.12(0.04 to 3478.54)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000121.91(40.58 to 366.25)
OG001108.81(25.43 to 456.54)
OG00217.31(3.99 to 75.02)
OG00311.53(1.92 to 69.27)
OG00425.41(6.70 to 96.36)
OG00584.18(9.28 to 763.81)
OG00610.54(1.40 to 79.41)
OG0076.70(0.00 to 1391842.10)
20.2886
(0.9428 to 436.6000)
14.0063
(0.1665 to 1177.9649)
7.8418
(0.0258 to 2386.5676)
333.0359
(37.2009 to 2981.4568)
7.3983
(0.0509 to 1074.6821)
28.7301
(8.8988 to 92.7564)
40.2809
(37.7735 to 42.9548)
45.4538
(8.0394 to 256.9892)
9.2994
(2.4248 to 35.6642)
5.0000
(NA to NA)
95% CI was not estimable because all values were equal.
119.8892
(29.6697 to 484.4483)
86.0638
(7.4913 to 988.7447)
49.9195
(5.0654 to 491.9535)
1491.6390
(87.0789 to 25551.3913)
653.5897
(7.3041 to 58484.7192)
5.0000
(NA to NA)
95% CI was not estimable because all values were equal.
5.0000
(NA to NA)
95% CI was not estimable because all values were equal.
5.0000
(NA to NA)
95% CI was not estimable because all values were equal.
6.6902
(1.9111 to 23.4209)
8.1121
(1.0113 to 65.0699)
95.1328
(16.7198 to 541.2903)
85.4674
(2.2603 to 3231.7721)
85.2857
(26.9267 to 270.1280)
74.1983
(0.1843 to 29875.2865)
482.9330
(137.4325 to 1697.0099)
OG004375.5394(190.3402 to 740.9358)
OG005146.8761(45.1229 to 478.0846)
OG006430.2308(92.9329 to 1991.7444)
OG0071843.1744(0.3234 to 10504058.3536)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000376.1197(235.0324 to 601.9001)
OG0011237.9613(480.9811 to 3186.2961)
OG002682.4080(360.8116 to 1290.6475)
OG003921.5980(346.0068 to 2454.6999)
OG004761.2916(431.8043 to 1342.1935)
OG005315.1407(151.7524 to 654.4454)
OG006652.4332(191.6513 to 2221.0601)
OG00711176.4335(0.0710 to 1758617910.3834)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000566.1029(310.8710 to 1030.8861)
OG0011468.7289(530.3009 to 4067.8127)
OG002829.7727(390.3204 to 1763.9937)
OG0031341.1447(559.6738 to 3213.7810)
OG0041229.6606(688.3558 to 2196.6330)
OG005425.4411(208.6954 to 867.2936)
OG0061230.7704(594.6819 to 2547.2370)
OG0078381.4354(14.7590 to 4759715.1788)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000559.7445(298.3456 to 1050.1710)
OG0011371.6395(454.2866 to 4141.4273)
OG0021114.9642(426.7668 to 2912.9379)
OG0031963.1115(1292.6702 to 2981.2762)
OG0042175.7877(1014.0073 to 4668.6570)
OG0051670.9884(372.7901 to 7490.0121)
OG0064276.7890(1271.4749 to 14385.5953)
OG0075078.3770(49.8822 to 517016.7435)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0001601.5347(823.4208 to 3114.9483)
OG0012738.3033(664.2616 to 11288.1810)
OG0021853.2904(545.1221 to 6300.7635)
OG0033188.0320(1267.3274 to 8019.6704)
OG0041229.7755(675.5304 to 2238.7562)
OG0051986.5339(262.9892 to 15005.6244)
OG0062813.3790(583.7984 to 13557.9362)
OG0073462.6712(2.3614 to 5077595.0850)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0003531.7642(1394.6079 to 8943.9897)
OG0016195.9903(1670.4600 to 22981.8713)
OG0021029.1579(368.6714 to 2872.9267)
OG0032333.8724(840.6688 to 6479.3176)
OG0041936.6356(964.5537 to 3888.3864)
OG0053228.9682(746.0332 to 13975.5651)
OG0061093.8728(234.7605 to 5096.9292)
OG0071645.4066(0.0011 to 2410518823.8906)
81.1329
(15.5453 to 423.4417)
OG00487.9255(46.7925 to 165.2165)
OG00548.7041(18.6670 to 127.0739)
OG006116.3880(18.7014 to 724.3415)
OG007468.5976(0.4353 to 504394.7664)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00085.6574(35.4915 to 206.7310)
OG001165.3657(41.7470 to 655.0362)
OG00277.0553(25.3844 to 233.9036)
OG003141.2683(33.7834 to 590.7255)
OG004173.5413(88.2833 to 341.1356)
OG00597.9557(47.8716 to 200.4384)
OG006209.5990(42.1687 to 1041.8084)
OG0072008.1706(0.5760 to 7001401.5955)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000153.6259(58.3967 to 404.1487)
OG001238.4406(50.3259 to 1129.7139)
OG002109.1945(40.5282 to 294.2012)
OG003196.8757(52.8512 to 733.3804)
OG004253.2367(136.9000 to 468.4357)
OG005123.3706(47.8388 to 318.1582)
OG006438.3675(121.7932 to 1577.8064)
OG0072467.0800(0.0739 to 82360112.6459)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000138.0929(52.0824 to 366.1436)
OG001244.4228(47.9172 to 1246.7870)
OG002246.0892(79.8529 to 758.3938)
OG003530.9893(214.1227 to 1316.7668)
OG004379.9728(193.7003 to 745.3749)
OG005596.9179(78.0512 to 4565.0904)
OG0061369.4248(272.2749 to 6887.6128)
OG0071833.8419(124.8388 to 26938.5377)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000329.7767(141.6572 to 767.7171)
OG001447.3343(102.5193 to 1951.9041)
OG002665.0024(139.2378 to 3176.0653)
OG003711.0995(250.9232 to 2015.2079)
OG004294.2032(145.0665 to 596.6614)
OG005757.4496(74.4007 to 7711.3502)
OG006711.7177(129.7126 to 3905.1120)
OG0071459.7959(8.5217 to 250067.9289)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0001779.4509(604.7857 to 5235.6489)
OG0012484.3099(791.0434 to 7802.0952)
OG002481.6709(137.6787 to 1685.1324)
OG003959.9418(208.3283 to 4423.2495)
OG004875.2497(310.8785 to 2464.1849)
OG0052147.7815(591.9922 to 7792.2734)
OG006546.5955(40.5298 to 7371.5336)
OG007685.0752(0.0000 to 11793589460.228)
94.0770
(24.5317 to 360.7774)
OG00438.4049(15.5880 to 94.6198)
OG00521.0485(7.7796 to 56.9487)
OG00663.8694(15.6348 to 260.9104)
OG007124.2137(1.3374 to 11536.4856)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00054.0724(22.1313 to 132.1128)
OG00182.9652(24.0835 to 285.8065)
OG002154.9099(69.5129 to 345.2179)
OG00394.8682(31.8399 to 282.6637)
OG00494.5667(41.9028 to 213.4191)
OG00536.6182(10.7558 to 124.6664)
OG006118.0503(27.7902 to 501.4678)
OG007571.0459(0.0451 to 7223499.3503)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00080.7230(30.7358 to 212.0074)
OG001116.9255(28.5017 to 479.6755)
OG002280.1679(103.4819 to 758.5292)
OG003155.9792(51.1285 to 475.8505)
OG004165.0762(80.5052 to 338.4896)
OG00538.3975(9.7908 to 150.5874)
OG006233.6561(91.3256 to 597.8077)
OG007717.7161(0.0006 to 863132368.1932)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00076.0077(29.2176 to 197.7290)
OG001129.8719(32.8448 to 513.5278)
OG002258.4824(73.2796 to 911.7565)
OG003277.7532(110.8690 to 695.8376)
OG004252.6360(101.3142 to 629.9702)
OG005236.6733(18.6894 to 2997.1096)
OG006742.6808(85.4290 to 6456.5250)
OG0071134.9309(32.8588 to 39200.0612)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000298.6044(143.5689 to 621.0575)
OG001324.0669(58.6172 to 1791.6126)
OG002575.9687(91.2214 to 3636.6469)
OG003627.1003(173.6712 to 2264.3642)
OG004170.1065(67.3139 to 429.8701)
OG005458.4044(27.4780 to 7647.3637)
OG006360.5940(32.6915 to 3977.4306)
OG0071380.7990(0.0475 to 40130153.0367)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0001688.7466(444.3317 to 6418.3249)
OG0012600.2491(446.5774 to 15140.2551)
OG002793.2778(316.7655 to 1986.6105)
OG0031084.8950(284.6646 to 4134.6809)
OG004976.0525(311.5167 to 3058.1940)
OG0051771.7935(321.8672 to 9753.2512)
OG006673.1993(50.3999 to 8992.0307)
OG007832.4483(0.0000 to 16056966235.924)
1.3351
(0.3850 to 4.6304)
2.3206
(1.8668 to 2.8847)
1.5100
(0.0080 to 283.7685)
5.8002
(2.3386 to 14.3857)
3.4419
(1.9292 to 6.1409)
3.3980
(1.8922 to 6.1019)
3.5077
(2.2207 to 5.5406)
4.3799
(2.5683 to 7.4694)
4.1463
(2.8173 to 6.1023)
3.9733
(2.8684 to 5.5037)
5.2318
(3.5862 to 7.6325)
5.2214
(2.9214 to 9.3321)
5.2627
(4.6084 to 6.0099)
OG0045.1098(4.5935 to 5.6842)
OG0054.3709(3.9083 to 4.8882)
OG0064.7219(3.6673 to 6.0797)
OG0075.1950(5.0078 to 5.3891)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0006.1134(5.8874 to 6.3480)
OG0016.3735(6.0264 to 6.7406)
OG0025.4103(4.9309 to 5.9362)
OG0035.5201(5.0123 to 6.0792)
OG0045.2454(4.8127 to 5.7169)
OG0054.6996(4.3467 to 5.0811)
OG0064.8502(4.1286 to 5.6979)
OG0076.3734(2.9596 to 13.7249)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0006.1962(5.7981 to 6.6217)
OG0016.2725(5.9372 to 6.6266)
OG0025.5427(5.1023 to 6.0211)
OG0035.2341(4.8568 to 5.6407)
OG0045.4238(5.1794 to 5.6798)
OG0054.7917(4.4116 to 5.2046)
OG0065.1222(4.4543 to 5.8903)
OG0076.1749(5.7458 to 6.6360)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0005.9271(5.6065 to 6.2659)
OG0016.2709(5.8290 to 6.7462)
OG0025.5019(5.0364 to 6.0103)
OG0035.3951(4.9673 to 5.8598)
OG0045.6756(5.1714 to 6.2289)
OG0055.4978(4.8782 to 6.1960)
OG0065.7671(5.1604 to 6.4451)
OG0076.5832(3.6902 to 11.7441)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0006.1082(5.7059 to 6.5388)
OG0016.3086(5.8666 to 6.7838)
OG0025.4872(4.8885 to 6.1593)
OG0035.5874(5.1392 to 6.0747)
OG0045.4714(4.9852 to 6.0050)
OG0055.5399(4.7833 to 6.4160)
OG0065.6336(4.8726 to 6.5134)
OG0076.2200(NA to NA)95% CI was not estimable because all values were equal.
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0005.6975(5.2935 to 6.1324)
OG0015.8714(5.3733 to 6.4157)
OG0025.8233(5.3127 to 6.3829)
OG0035.9260(5.4429 to 6.4519)
OG0045.8235(5.2837 to 6.4185)
OG0056.0125(5.4342 to 6.6523)
OG0065.3922(4.4939 to 6.4702)
OG0075.5803(2.6334 to 11.8249)
1.9543
(0.4462 to 8.5590)
2.6772
(1.4588 to 4.9135)
1.6279
(0.0033 to 795.3299)
4.6257
(2.6709 to 8.0111)
3.3798
(2.4180 to 4.7244)
3.3500
(2.4830 to 4.5198)
3.2201
(2.6540 to 3.9070)
4.0985
(2.5970 to 6.4679)
3.9677
(2.8054 to 5.6116)
3.5196
(2.5478 to 4.8622)
4.7234
(3.3074 to 6.7455)
4.8462
(2.7734 to 8.4683)
5.2196
(4.6659 to 5.8390)
OG0045.1658(4.7844 to 5.5778)
OG0054.5890(3.9383 to 5.3472)
OG0065.3462(4.6020 to 6.2108)
OG0075.1096(2.8489 to 9.1641)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0005.7415(5.5118 to 5.9807)
OG0016.0642(5.6893 to 6.4639)
OG0025.0168(4.6097 to 5.4600)
OG0035.2691(4.8097 to 5.7724)
OG0045.5084(5.1758 to 5.8623)
OG0055.0731(4.6581 to 5.5252)
OG0065.3743(4.6002 to 6.2786)
OG0076.1184(3.3860 to 11.0557)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0006.0318(5.6884 to 6.3960)
OG0016.0754(5.6760 to 6.5028)
OG0025.1947(4.6974 to 5.7447)
OG0035.5926(5.1392 to 6.0859)
OG0045.6533(5.4356 to 5.8797)
OG0055.0920(4.5783 to 5.6633)
OG0065.6380(5.0530 to 6.2907)
OG0075.5236(4.1434 to 7.3636)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0005.7937(5.5268 to 6.0734)
OG0016.0462(5.5754 to 6.5569)
OG0024.8845(4.4528 to 5.3580)
OG0035.1933(4.8645 to 5.5444)
OG0045.8548(5.4504 to 6.2892)
OG0055.4640(4.8358 to 6.1737)
OG0065.8416(5.1800 to 6.5878)
OG0076.4489(5.0911 to 8.1689)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0005.5115(5.0201 to 6.0510)
OG0015.5887(4.9609 to 6.2961)
OG0024.7663(4.3033 to 5.2790)
OG0035.2681(4.8152 to 5.7635)
OG0045.5167(5.1231 to 5.9405)
OG0055.5953(4.8132 to 6.5044)
OG0065.6251(4.8903 to 6.4703)
OG0075.7356(0.7961 to 41.3242)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0005.1647(4.7379 to 5.6300)
OG0015.5361(4.9747 to 6.1608)
OG0024.8448(4.5241 to 5.1882)
OG0035.3569(4.8486 to 5.9184)
OG0045.3687(4.9860 to 5.7809)
OG0055.3688(4.6880 to 6.1484)
OG0065.1322(4.4562 to 5.9108)
OG0075.0425(1.7521 to 14.5125)
33
(1 to 91)
50
(1 to 99)
100
(16 to 100)
50
(1 to 99)
100
(16 to 100)
100
(16 to 100)
67
(9 to 99)
0
(0 to 71)
100
(29 to 100)
100
(29 to 100)
100
(29 to 100)
100
(29 to 100)
100
(29 to 100)
0
(0 to 71)
0
(0 to 71)
33
(1 to 91)
33
(1 to 91)
100
(29 to 100)
100
(29 to 100)
100
(29 to 100)
100
(29 to 100)
100
(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(69 to 100)
OG001100(69 to 100)
OG002100(63 to 100)
OG003100(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(69 to 100)
OG001100(69 to 100)
OG002100(63 to 100)
OG003100(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(69 to 100)
OG001100(69 to 100)
OG002100(63 to 100)
OG003100(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(66 to 100)
OG001100(69 to 100)
OG002100(63 to 100)
OG003100(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
90
(55 to 99)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(69 to 100)
OG00190(55 to 99)
OG002100(63 to 100)
OG003100(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(69 to 100)
OG00190(55 to 99)
OG002100(63 to 100)
OG003100(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(69 to 100)
OG001100(69 to 100)
OG002100(63 to 100)
OG003100(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(66 to 100)
OG001100(69 to 100)
OG002100(63 to 100)
OG003100(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG00686(42 to 99)
OG007100(16 to 100)
90
(55 to 99)
OG004100(69 to 100)
OG00586(42 to 99)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00090(55 to 99)
OG00190(55 to 99)
OG002100(63 to 100)
OG00390(55 to 99)
OG004100(69 to 100)
OG00586(42 to 99)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00090(55 to 99)
OG00190(55 to 99)
OG002100(63 to 100)
OG003100(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(69 to 100)
OG001100(69 to 100)
OG002100(63 to 100)
OG003100(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
ParticipantsOG00410
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000100(66 to 100)
OG001100(69 to 100)
OG002100(63 to 100)
OG003100(69 to 100)
OG004100(69 to 100)
OG005100(59 to 100)
OG006100(59 to 100)
OG007100(16 to 100)
0.078
(-0.896 to 1.051)
0.090
(-0.819 to 1.000)
0.004
(-0.035 to 0.043)
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.026
(-0.074 to 0.126)
0.017
(-0.005 to 0.040)
0.016
(-0.007 to 0.039)
0.019
(-0.059 to 0.097)
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.004
(-0.010 to 0.019)
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.003
(-0.005 to 0.011)
0.003
(-0.006 to 0.011)
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.001
(0.000 to 0.003)
0.005
(-0.013 to 0.024)
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.001
(0.001 to 0.001)
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.004
(-0.010 to 0.018)
0.005
(-0.011 to 0.020)
0.001
(-0.000 to 0.003)
0.001
(-0.000 to 0.003)
0.004
(-0.010 to 0.019)
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
0.006
(-0.016 to 0.028)
0.002
(-0.003 to 0.008)
0.003
(-0.007 to 0.014)
0.099
(0.018 to 0.180)
OG0040.237(0.091 to 0.383)
OG0050.166(0.060 to 0.272)
OG0060.149(-0.005 to 0.304)
OG0070.103(-0.563 to 0.768)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.192(0.108 to 0.276)
OG0010.316(0.084 to 0.547)
OG0020.225(0.098 to 0.353)
OG0030.111(0.029 to 0.193)
OG0040.252(0.139 to 0.365)
OG0050.172(0.082 to 0.262)
OG0060.228(0.014 to 0.443)
OG0070.223(-1.995 to 2.442)
0.006
(0.001 to 0.010)
OG0040.015(-0.003 to 0.033)
OG0050.007(-0.006 to 0.020)
OG0060.004(-0.001 to 0.009)
OG0070.001(NA to NA)95% CI was not estimable because all values were equal.
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.003(-0.001 to 0.008)
OG0010.008(-0.000 to 0.016)
OG0020.004(0.001 to 0.008)
OG0030.004(-0.000 to 0.008)
OG0040.015(0.000 to 0.029)
OG0050.004(-0.003 to 0.011)
OG0060.012(-0.001 to 0.025)
OG0070.003(-0.019 to 0.024)
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
OG0040.010(-0.009 to 0.028)
OG0050.007(-0.006 to 0.019)
OG0060.002(-0.000 to 0.005)
OG0070.003(-0.019 to 0.025)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.019(-0.005 to 0.043)
OG0010.015(0.000 to 0.030)
OG0020.022(-0.023 to 0.067)
OG0030.001(NA to NA)95% CI was not estimable because all values were equal.
OG0040.014(-0.004 to 0.033)
OG0050.007(-0.001 to 0.014)
OG0060.011(-0.005 to 0.027)
OG0070.006(-0.016 to 0.028)
0.005
(-0.001 to 0.011)
OG0040.005(-0.002 to 0.012)
OG0050.012(-0.001 to 0.025)
OG0060.008(0.000 to 0.016)
OG0070.011(-0.006 to 0.029)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.001(0.001 to 0.002)
OG0010.004(0.000 to 0.007)
OG0020.006(-0.002 to 0.013)
OG0030.003(-0.001 to 0.007)
OG0040.005(-0.001 to 0.011)
OG0050.002(-0.001 to 0.005)
OG0060.004(-0.001 to 0.009)
OG0070.001(-0.005 to 0.008)
0.002
(-0.000 to 0.004)
OG0040.002(-0.001 to 0.005)
OG0050.001(0.001 to 0.002)
OG0060.001(NA to NA)95% CI was not estimable because all values were equal.
OG0070.001(-0.003 to 0.006)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.014(-0.004 to 0.033)
OG0010.011(0.003 to 0.019)
OG0020.002(0.001 to 0.002)
OG0030.001(NA to NA)95% CI was not estimable because all values were equal.
OG0040.003(0.000 to 0.006)
OG0050.003(-0.001 to 0.006)
OG0060.005(0.000 to 0.009)
OG0070.002(-0.014 to 0.019)
0.002
(0.000 to 0.004)
OG0040.003(-0.000 to 0.005)
OG0050.002(0.000 to 0.003)
OG0060.002(0.000 to 0.005)
OG0070.002(-0.014 to 0.019)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.002(-0.000 to 0.004)
OG0010.003(0.000 to 0.005)
OG0020.003(-0.001 to 0.006)
OG0030.002(0.001 to 0.003)
OG0040.001(0.001 to 0.002)
OG0050.001(NA to NA)95% CI was not estimable because all values were equal.
OG0060.002(0.000 to 0.003)
OG0070.001(NA to NA)95% CI was not estimable because all values were equal.
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
OG0040.007(-0.002 to 0.016)
OG0050.005(-0.001 to 0.010)
OG0060.008(-0.007 to 0.023)
OG0070.004(-0.034 to 0.042)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.002(-0.000 to 0.004)
OG0010.002(0.001 to 0.003)
OG0020.019(-0.021 to 0.058)
OG0030.001(NA to NA)95% CI was not estimable because all values were equal.
OG0040.008(-0.001 to 0.017)
OG0050.008(-0.004 to 0.019)
OG0060.010(-0.012 to 0.033)
OG0070.003(-0.018 to 0.024)
0.002
(0.000 to 0.004)
OG0040.004(-0.002 to 0.010)
OG0050.005(-0.001 to 0.012)
OG0060.002(0.001 to 0.003)
OG0070.011(-0.081 to 0.103)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.001(0.001 to 0.001)
OG0010.001(0.001 to 0.002)
OG0020.005(-0.003 to 0.012)
OG0030.002(0.000 to 0.003)
OG0040.002(0.001 to 0.003)
OG0050.003(-0.001 to 0.007)
OG0060.002(-0.000 to 0.005)
OG0070.001(NA to NA)95% CI was not estimable because all values were equal.
0.001
(NA to NA)
95% CI was not estimable because all values were equal.
OG0040.004(-0.003 to 0.011)
OG0050.003(-0.002 to 0.009)
OG0060.003(-0.001 to 0.008)
OG0070.001(NA to NA)95% CI was not estimable because all values were equal.
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.004(-0.002 to 0.011)
OG0010.009(-0.001 to 0.019)
OG0020.007(-0.005 to 0.019)
OG0030.001(NA to NA)95% CI was not estimable because all values were equal.
OG0040.006(-0.002 to 0.014)
OG0050.001(0.001 to 0.002)
OG0060.003(0.001 to 0.006)
OG0070.005(-0.044 to 0.055)
0.003
(-0.000 to 0.006)
OG0040.001(NA to NA)95% CI was not estimable because all values were equal.
OG0050.009(0.001 to 0.017)
OG0060.009(-0.003 to 0.021)
OG0070.003(-0.023 to 0.029)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000.001(0.001 to 0.002)
OG0010.002(-0.000 to 0.004)
OG0020.001(0.001 to 0.002)
OG0030.002(0.000 to 0.004)
OG0040.005(-0.001 to 0.010)
OG0050.005(-0.004 to 0.015)
OG0060.004(-0.002 to 0.010)
OG0070.006(-0.061 to 0.074)
50
(1 to 99)
50
(1 to 99)
0
(0 to 84)
0
(0 to 84)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
0
(0 to 71)
38
(9 to 76)
OG00470(35 to 93)
OG00567(22 to 96)
OG00657(18 to 90)
OG00750(1 to 99)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00089(52 to 99)
OG00180(44 to 97)
OG002100(63 to 100)
OG00356(21 to 86)
OG00480(44 to 97)
OG00567(22 to 96)
OG00686(42 to 99)
OG00750(1 to 99)
0
(0 to 37)
OG00420(3 to 56)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 34)
OG0010(0 to 31)
OG0020(0 to 37)
OG0030(0 to 34)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
0
(0 to 37)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00011(1 to 48)
OG0010(0 to 31)
OG00213(1 to 53)
OG0030(0 to 34)
OG00420(3 to 56)
OG0050(0 to 46)
OG00614(1 to 58)
OG0070(0 to 84)
0
(0 to 37)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 34)
OG0010(0 to 31)
OG0020(0 to 37)
OG0030(0 to 34)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
0
(0 to 37)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00011(1 to 48)
OG0010(0 to 31)
OG0020(0 to 37)
OG0030(0 to 34)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
0
(0 to 37)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 34)
OG0010(0 to 31)
OG0020(0 to 37)
OG0030(0 to 34)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
0
(0 to 37)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 34)
OG0010(0 to 31)
OG00213(1 to 53)
OG0030(0 to 34)
OG00420(3 to 56)
OG0050(0 to 46)
OG00614(1 to 58)
OG0070(0 to 84)
0
(0 to 37)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 34)
OG0010(0 to 31)
OG0020(0 to 37)
OG0030(0 to 34)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
0
(0 to 37)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 34)
OG0010(0 to 31)
OG0020(0 to 37)
OG0030(0 to 34)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
0
(0 to 37)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
ParticipantsOG00410
ParticipantsOG0056
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG0000(0 to 34)
OG0010(0 to 31)
OG0020(0 to 37)
OG0030(0 to 34)
OG0040(0 to 31)
OG0050(0 to 46)
OG0060(0 to 41)
OG0070(0 to 84)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
51.250
(-409.350 to 511.850)
37.500
(-248.390 to 323.390)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
18.333
(3.991 to 32.676)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
29.167
(-31.788 to 90.121)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
37.500
(-248.390 to 323.390)
230.000
(-2184.179 to 2644.179)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
25.000
(-102.062 to 152.062)
90.000
(-862.965 to 1042.965)
26.667
(-23.531 to 76.864)
19.167
(1.239 to 37.094)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
166.250
(-1755.563 to 2088.063)
20.000
(-1.513 to 41.513)
27.500
(-11.284 to 66.284)
28.750
(-145.960 to 203.460)
177.500
(-1791.962 to 2146.962)
29.167
(-31.788 to 90.121)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
55.000
(-453.248 to 563.248)
312.500
(-3149.941 to 3774.941)
36.667
(-56.557 to 129.891)
25.000
(-18.027 to 68.027)
28.750
(-145.960 to 203.460)
332.500
(-3701.720 to 4366.720)
55.833
(-119.858 to 231.525)
25.000
(-18.027 to 68.027)
76.250
(-702.005 to 854.505)
637.500
(-6954.457 to 8229.457)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
51.250
(-409.350 to 511.850)
37.500
(-248.390 to 323.390)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
27.500
(-7.078 to 62.078)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
17.500
(6.743 to 28.257)
23.333
(-12.522 to 59.189)
24.167
(-15.274 to 63.608)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
24.167
(2.357 to 45.977)
43.750
(-321.553 to 409.053)
35.833
(-9.944 to 81.610)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
17.500
(6.743 to 28.257)
28.333
(-29.035 to 85.702)
328.333
(-688.521 to 1345.188)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
17.500
(6.743 to 28.257)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
72.500
(-174.903 to 319.903)
83.333
(-99.248 to 265.915)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
20.000
(-43.531 to 83.531)
25.000
(0.159 to 49.841)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
22.500
(6.069 to 38.931)
17.500
(6.743 to 28.257)
74.167
(-110.306 to 258.639)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
20.000
(-43.531 to 83.531)
21.667
(-7.018 to 50.351)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
24.167
(-15.274 to 63.608)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
20.833
(-4.265 to 45.932)
43.750
(-321.553 to 409.053)
35.833
(-9.944 to 81.610)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
90.833
(-235.451 to 417.118)
404.167
(-637.661 to 1445.994)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
33.333
(-45.549 to 112.215)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
24.167
(-15.274 to 63.608)
74.167
(-110.306 to 258.639)
20.833
(-4.265 to 45.932)
43.750
(-321.553 to 409.053)
59.167
(-76.090 to 194.423)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
105.000
(-282.239 to 492.239)
473.333
(-616.760 to 1563.427)
24.167
(-15.274 to 63.608)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
23.333
(-12.522 to 59.189)
24.167
(-15.274 to 63.608)
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
OG00416.111(13.549 to 18.673)
OG00515.00(NA to NA)95% CI was not estimable because all values were equal.
OG00615.00(NA to NA)95% CI was not estimable because all values were equal.
OG00715.00(NA to NA)95% CI was not estimable because all values were equal.
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00021.944(14.964 to 28.925)
OG00116.750(12.791 to 20.709)
OG00218.438(10.309 to 26.566)
OG00317.000(13.984 to 20.016)
OG00415.000(NA to NA)95% CI was not estimable because all values were equal.
OG00518.93(11.88 to 25.97)
OG00615.00(NA to NA)95% CI was not estimable because all values were equal.
OG00715.00(NA to NA)95% CI was not estimable because all values were equal.
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0066
ParticipantsOG0072
Title
Measurements
OG00019.688(11.445 to 27.930)
OG00118.889(12.294 to 25.484)
OG00217.188(12.015 to 22.360)
OG00316.000(13.738 to 18.262)
OG00417.500(11.735 to 23.265)
OG00515.00(NA to NA)95% CI was not estimable because all values were equal.
OG00615.00(NA to NA)95% CI was not estimable because all values were equal.
OG00715.00(NA to NA)95% CI was not estimable because all values were equal.
ParticipantsOG0049
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG00017.813(13.147 to 22.478)
OG00115.000(NA to NA)95% CI was not estimable because all values were equal.
OG00217.813(13.423 to 22.202)
OG00320.250(13.326 to 27.174)
OG00415.000(NA to NA)95% CI was not estimable because all values were equal.
OG00515.00(NA to NA)95% CI was not estimable because all values were equal.
OG00615.00(NA to NA)95% CI was not estimable because all values were equal.
OG00715.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
ParticipantsOG0049
ParticipantsOG0053
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG00017.500(13.657 to 21.343)
OG00122.813(10.706 to 34.919)
OG00215.938(13.721 to 18.154)
OG00330.750(-4.879 to 66.379)
OG00416.111(13.549 to 18.673)
OG00515.00(NA to NA)95% CI was not estimable because all values were equal.
OG00615.00(NA to NA)95% CI was not estimable because all values were equal.
OG00715.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
17.778
(11.372 to 24.183)
OG00425.278(1.577 to 48.978)
OG00516.79(12.42 to 21.16)
OG00625.71(-0.50 to 51.93)
OG00715.00(NA to NA)95% CI was not estimable because all values were equal.
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00019.167(12.373 to 25.961)
OG00125.500(14.776 to 36.224)
OG00277.188(-59.033 to 213.408)
OG00319.000(9.951 to 28.049)
OG00417.500(11.735 to 23.265)
OG00520.36(11.87 to 28.84)
OG00628.93(3.47 to 54.39)
OG007206.25(-2223.81 to 2636.31)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0066
ParticipantsOG0072
Title
Measurements
OG00023.125(16.732 to 29.518)
OG00128.333(11.498 to 45.169)
OG00255.625(-31.348 to 142.598)
OG00319.000(9.951 to 28.049)
OG00418.611(10.284 to 26.938)
OG00522.50(10.64 to 34.36)
OG00645.00(-4.47 to 94.47)
OG007666.25(-7608.67 to 8941.17)
ParticipantsOG0049
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG00025.938(10.622 to 41.253)
OG00132.000(11.284 to 52.716)
OG00264.375(-29.772 to 158.522)
OG00321.500(6.796 to 36.204)
OG00421.944(5.931 to 37.958)
OG00515.00(NA to NA)95% CI was not estimable because all values were equal.
OG00628.75(-15.01 to 72.51)
OG00715.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
ParticipantsOG0049
ParticipantsOG0053
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG00051.111(-12.798 to 115.020)
OG00134.688(15.356 to 54.019)
OG00243.125(3.113 to 83.137)
OG00336.750(4.338 to 69.162)
OG00421.389(6.656 to 36.122)
OG00517.50(6.74 to 28.26)
OG00654.38(-60.57 to 169.32)
OG00715.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
15.000
(NA to NA)
95% CI was not estimable because all values were equal.
OG00422.500(7.247 to 37.753)
OG00519.64(10.95 to 28.34)
OG00617.14(13.76 to 20.53)
OG00731.25(-175.23 to 237.73)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00046.667(21.101 to 72.233)
OG00118.889(12.294 to 25.484)
OG00231.250(6.369 to 56.131)
OG00319.250(11.339 to 27.161)
OG00420.556(11.605 to 29.506)
OG00526.07(6.55 to 45.59)
OG00626.79(0.88 to 52.69)
OG00770.00(-628.84 to 768.84)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0066
ParticipantsOG0072
Title
Measurements
OG00044.063(27.307 to 60.818)
OG00131.944(2.116 to 61.773)
OG00242.188(9.512 to 74.863)
OG00321.250(7.112 to 35.388)
OG00428.056(8.136 to 47.975)
OG00529.29(10.95 to 47.62)
OG00627.50(-0.95 to 55.95)
OG007157.50(-1557.84 to 1872.84)
ParticipantsOG0049
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG00026.250(14.166 to 38.334)
OG00122.750(8.088 to 37.412)
OG00237.813(13.530 to 62.095)
OG00322.000(13.536 to 30.464)
OG00424.167(6.925 to 41.408)
OG00517.50(9.54 to 25.46)
OG00620.63(2.72 to 38.53)
OG00715.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
ParticipantsOG0049
ParticipantsOG0053
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG00030.278(4.885 to 55.671)
OG00134.688(14.472 to 54.903)
OG00223.750(10.159 to 37.341)
OG00324.000(3.641 to 44.359)
OG00419.722(8.833 to 30.612)
OG00518.33(3.99 to 32.68)
OG00618.13(8.18 to 28.07)
OG00722.50(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
56.389
(23.804 to 88.974)
OG004137.500(-119.160 to 394.160)
OG005118.21(38.91 to 197.52)
OG006197.50(-70.02 to 465.02)
OG007208.75(-2157.78 to 2575.28)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000160.278(80.381 to 240.174)
OG001130.000(51.905 to 208.095)
OG002137.813(43.595 to 232.030)
OG003117.000(7.183 to 226.817)
OG004117.500(-31.708 to 266.708)
OG005132.50(21.40 to 243.60)
OG006437.86(-118.32 to 994.03)
OG007827.50(-8416.26 to 10071.26)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0066
ParticipantsOG0072
Title
Measurements
OG000153.438(109.271 to 197.604)
OG001151.000(46.413 to 255.587)
OG002163.750(-3.987 to 331.487)
OG003146.000(-51.075 to 343.075)
OG004117.222(-36.870 to 271.314)
OG005140.71(51.48 to 229.95)
OG006431.25(-119.11 to 981.61)
OG0071157.50(-12025.19 to 14340.19)
ParticipantsOG0049
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000118.438(69.359 to 167.516)
OG001157.000(85.242 to 228.758)
OG002170.313(45.436 to 295.189)
OG003117.750(-6.487 to 241.987)
OG004105.278(-79.354 to 289.909)
OG00573.75(17.26 to 130.24)
OG006412.50(-403.44 to 1228.44)
OG00740.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
ParticipantsOG0049
ParticipantsOG0053
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000201.389(-8.577 to 411.355)
OG001195.938(-36.806 to 428.681)
OG002112.500(49.204 to 175.796)
OG003210.750(-110.210 to 531.710)
OG00495.833(-50.419 to 242.086)
OG00582.50(-20.86 to 185.86)
OG006415.00(-327.27 to 1157.27)
OG00745.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
61.389
(30.536 to 92.242)
OG004124.167(-26.541 to 274.874)
OG005108.57(25.71 to 191.43)
OG00658.57(-3.85 to 121.00)
OG007576.25(-6555.11 to 7707.61)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000143.056(107.417 to 178.694)
OG001143.500(47.780 to 239.220)
OG002116.563(38.201 to 194.924)
OG003104.500(24.918 to 184.082)
OG004124.167(19.753 to 228.580)
OG005127.14(33.69 to 220.60)
OG00687.86(-9.64 to 185.35)
OG0071006.25(-11048.76 to 13061.26)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0066
ParticipantsOG0072
Title
Measurements
OG000146.875(93.545 to 200.205)
OG001183.889(61.342 to 306.436)
OG002150.625(-17.364 to 318.614)
OG003115.000(35.154 to 194.846)
OG004131.667(-2.010 to 265.344)
OG005139.64(41.41 to 237.88)
OG00693.75(3.97 to 183.53)
OG0071360.00(-15634.55 to 18354.55)
ParticipantsOG0049
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000101.563(68.744 to 134.381)
OG001158.750(65.547 to 251.953)
OG002155.938(14.868 to 297.007)
OG003101.750(33.880 to 169.620)
OG004116.667(-10.516 to 243.849)
OG00595.00(-9.50 to 199.50)
OG00683.13(-79.26 to 245.51)
OG00725.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
ParticipantsOG0049
ParticipantsOG0053
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000143.611(81.260 to 205.963)
OG001486.875(-264.121 to 1237.871)
OG002125.313(43.335 to 207.290)
OG003166.750(-61.320 to 394.820)
OG00479.167(-4.321 to 162.654)
OG005122.50(-144.11 to 389.11)
OG00681.25(-17.08 to 179.58)
OG00715.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
101.111
(28.786 to 173.437)
OG004180.556(-150.518 to 511.630)
OG005182.14(45.45 to 318.83)
OG006126.43(-42.46 to 295.31)
OG00765.00(-570.31 to 700.31)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000159.444(86.720 to 232.169)
OG001155.500(66.695 to 244.305)
OG002128.438(41.837 to 215.038)
OG003132.750(30.697 to 234.803)
OG004134.772(-48.040 to 317.484)
OG005256.43(111.50 to 401.36)
OG006225.71(-66.22 to 517.65)
OG007206.25(-1906.16 to 2318.66)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0066
ParticipantsOG0072
Title
Measurements
OG000151.250(56.652 to 245.848)
OG001173.611(61.415 to 285.807)
OG002128.750(7.697 to 249.803)
OG003126.750(21.176 to 232.324)
OG004137.500(-72.220 to 347.220)
OG005269.29(113.82 to 424.75)
OG006245.42(-117.80 to 608.64)
OG007451.25(-4742.41 to 5644.91)
ParticipantsOG0049
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000130.625(52.648 to 208.602)
OG001199.000(69.122 to 328.878)
OG002139.063(40.074 to 238.051)
OG003119.000(41.022 to 196.978)
OG004135.833(-106.303 to 377.969)
OG005156.88(32.33 to 281.42)
OG006336.88(-596.26 to 1270.01)
OG00730.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
ParticipantsOG0049
ParticipantsOG0053
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000241.667(36.450 to 446.883)
OG001215.000(4.700 to 425.300)
OG00294.688(46.565 to 142.810)
OG003233.000(-136.739 to 602.739)
OG004109.444(-47.953 to 266.842)
OG005198.33(-20.47 to 417.14)
OG006217.50(-274.50 to 709.50)
OG00722.50(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
45.556
(8.110 to 83.001)
OG00453.333(-7.306 to 113.973)
OG00591.79(35.19 to 148.38)
OG00647.50(5.12 to 89.88)
OG00731.25(15.37 to 47.13)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00084.167(43.857 to 124.476)
OG00183.750(22.768 to 144.732)
OG00253.125(12.601 to 93.649)
OG00372.750(28.344 to 117.156)
OG00464.444(32.120 to 96.769)
OG005108.93(60.49 to 157.37)
OG00648.93(9.38 to 88.48)
OG00791.25(-496.41 to 678.91)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0066
ParticipantsOG0072
Title
Measurements
OG00081.250(45.361 to 117.139)
OG00191.944(28.531 to 155.358)
OG00267.500(23.616 to 111.384)
OG00380.500(23.441 to 137.559)
OG00458.333(16.177 to 100.490)
OG005121.43(70.18 to 172.68)
OG00650.42(19.98 to 80.85)
OG00778.75(-254.79 to 412.29)
ParticipantsOG0049
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG00056.563(28.994 to 84.131)
OG00171.250(15.035 to 127.465)
OG00261.875(29.733 to 94.017)
OG00367.750(21.134 to 114.366)
OG00479.722(-6.595 to 166.039)
OG00569.38(42.91 to 95.84)
OG00647.50(-48.14 to 143.14)
OG00725.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
ParticipantsOG0049
ParticipantsOG0053
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG00072.778(17.687 to 127.868)
OG001157.500(-65.975 to 380.975)
OG00242.813(18.325 to 67.300)
OG00377.250(7.861 to 146.639)
OG00451.944(12.918 to 90.971)
OG00580.83(-48.30 to 209.96)
OG00632.50(6.72 to 58.28)
OG00715.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
110.833
(47.142 to 174.524)
OG004247.778(-157.638 to 653.194)
OG005223.57(72.86 to 374.28)
OG006246.79(-66.71 to 560.28)
OG007773.75(-8867.08 to 10414.58)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000303.333(204.591 to 402.075)
OG001268.500(102.559 to 434.441)
OG002249.375(76.426 to 422.324)
OG003213.500(25.430 to 401.570)
OG004243.722(10.040 to 459.405)
OG005259.64(83.16 to 436.12)
OG006516.43(-140.55 to 1173.41)
OG0071833.75(-19465.03 to 23132.53)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0066
ParticipantsOG0072
Title
Measurements
OG000300.313(215.957 to 384.668)
OG001348.333(119.531 to 577.135)
OG002306.875(-29.828 to 643.578)
OG003254.250(-12.757 to 521.257)
OG004237.500(-35.436 to 510.436)
OG005276.43(99.66 to 453.20)
OG006520.83(-103.49 to 1145.16)
OG0072506.25(-27813.93 to 32826.43)
ParticipantsOG0049
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000218.125(147.869 to 288.381)
OG001313.250(171.078 to 455.422)
OG002322.500(58.245 to 586.755)
OG003212.750(21.941 to 403.559)
OG004209.444(-90.550 to 509.439)
OG005165.00(5.84 to 324.16)
OG006488.13(-490.54 to 1466.79)
OG00740.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
ParticipantsOG0049
ParticipantsOG0053
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000345.000(84.088 to 605.912)
OG001674.375(-213.067 to 1561.817)
OG002230.313(86.993 to 373.632)
OG003371.000(-179.486 to 921.486)
OG004160.556(-72.268 to 393.379)
OG005196.67(-198.77 to 592.10)
OG006486.25(-361.95 to 1334.45)
OG00745.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
136.667
(23.349 to 249.984)
OG004223.889(-169.836 to 617.613)
OG005273.93(86.23 to 461.62)
OG006164.64(-50.29 to 379.58)
OG00788.75(-657.74 to 835.24)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000238.611(138.564 to 338.659)
OG001233.750(90.039 to 377.461)
OG002174.688(54.237 to 295.138)
OG003191.500(40.265 to 342.735)
OG004190.278(-18.107 to 398.663)
OG005365.36(190.84 to 539.87)
OG006263.57(-67.56 to 594.70)
OG007297.50(-2402.57 to 2997.57)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0066
ParticipantsOG0072
Title
Measurements
OG000232.500(111.741 to 353.259)
OG001262.222(100.318 to 424.126)
OG002185.938(20.814 to 351.061)
OG003202.750(42.937 to 362.563)
OG004185.556(-66.879 to 437.990)
OG005390.71(200.45 to 580.98)
OG006289.58(-99.30 to 678.46)
OG007530.00(-4997.20 to 6057.20)
ParticipantsOG0049
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000183.438(81.132 to 285.743)
OG001262.750(98.821 to 426.679)
OG002190.313(55.127 to 325.498)
OG003178.750(56.888 to 300.612)
OG004203.056(-126.882 to 532.993)
OG005226.25(93.89 to 358.61)
OG006368.75(-676.45 to 1413.95)
OG00730.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
ParticipantsOG0049
ParticipantsOG0053
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000311.111(50.230 to 571.992)
OG001365.938(-65.269 to 797.144)
OG002130.313(54.283 to 206.342)
OG003303.500(-135.520 to 742.520)
OG004149.722(-47.484 to 346.929)
OG005279.17(-59.87 to 618.20)
OG006238.75(-289.24 to 766.74)
OG00715.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
245.833
(74.320 to 417.347)
OG004466.667(-331.690 to 1265.023)
OG005497.50(163.29 to 831.71)
OG006407.14(-65.93 to 880.22)
OG007855.00(-9627.62 to 11337.62)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG000541.944(361.956 to 721.933)
OG001500.750(198.369 to 803.131)
OG002424.063(139.388 to 708.737)
OG003399.000(61.306 to 736.694)
OG004423.333(-1.042 to 847.708)
OG005625.00(284.20 to 965.80)
OG006775.71(-196.03 to 1747.46)
OG0072131.25(-21867.59 to 26130.09)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0066
ParticipantsOG0072
Title
Measurements
OG000532.813(345.095 to 720.530)
OG001610.556(236.649 to 984.462)
OG002492.813(-5.871 to 991.496)
OG003452.500(33.223 to 871.777)
OG004418.056(-104.235 to 940.346)
OG005667.14(313.09 to 1021.20)
OG006807.92(-142.87 to 1758.71)
OG0073036.25(-32811.13 to 38883.63)
ParticipantsOG0049
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000401.563(246.202 to 556.923)
OG001576.000(288.467 to 863.533)
OG002510.938(117.787 to 904.088)
OG003390.000(86.109 to 693.891)
OG004405.833(-220.889 to 1032.556)
OG005391.25(100.83 to 681.67)
OG006849.38(-1148.74 to 2847.49)
OG00770.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
ParticipantsOG0049
ParticipantsOG0053
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG000656.111(138.931 to 1173.291)
OG0011038.438(-163.839 to 2240.714)
OG002360.625(147.341 to 573.909)
OG003670.000(-320.087 to 1660.087)
OG004305.278(-124.952 to 735.507)
OG005475.83(-257.94 to 1209.61)
OG006717.50(-597.31 to 2014.31)
OG00745.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
17.778
(11.372 to 24.183)
OG00433.611(-9.306 to 76.528)
OG00518.57(9.83 to 27.31)
OG00625.71(-0.50 to 51.93)
OG00731.25(-175.23 to 237.73)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0067
ParticipantsOG0072
Title
Measurements
OG00062.222(28.614 to 95.830)
OG00133.056(17.362 to 48.749)
OG00297.813(-65.874 to 261.499)
OG00322.500(11.158 to 33.842)
OG00424.722(9.276 to 40.169)
OG00538.57(-2.83 to 79.97)
OG00638.57(5.69 to 71.46)
OG007268.75(-2955.45 to 3492.95)
ParticipantsOG0049
ParticipantsOG0057
ParticipantsOG0066
ParticipantsOG0072
Title
Measurements
OG00057.500(33.801 to 81.199)
OG00149.444(9.356 to 89.533)
OG00289.688(-21.495 to 200.870)
OG00325.250(9.333 to 41.167)
OG00437.500(3.097 to 71.903)
OG00531.07(10.57 to 51.57)
OG00658.75(-20.82 to 138.32)
OG007812.50(-9320.70 to 10945.70)
ParticipantsOG0049
ParticipantsOG0054
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG00039.063(17.546 to 60.579)
OG00137.500(14.259 to 60.741)
OG00290.938(-25.018 to 206.893)
OG00337.500(5.464 to 69.536)
OG00432.778(-4.092 to 69.647)
OG00515.00(NA to NA)95% CI was not estimable because all values were equal.
OG00634.38(-7.01 to 75.76)
OG00715.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.
ParticipantsOG0049
ParticipantsOG0053
ParticipantsOG0064
ParticipantsOG0071
Title
Measurements
OG00068.611(-24.303 to 161.525)
OG00172.500(14.289 to 130.711)
OG00253.750(12.173 to 95.327)
OG00363.750(-30.692 to 158.192)
OG00427.778(-1.688 to 57.243)
OG00515.00(NA to NA)95% CI was not estimable because all values were equal.
OG00651.88(-65.48 to 169.23)
OG00715.00(NA to NA)95% CI was not estimable because only one participant was analyzed at this time point.